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CCR5 AND THE BLOOD BRAIN BARRIER DURING HIV-1 INFECTION AND CELLCELL COMMUNICATIONS
Shawna M. Woollard, Ph.D.
University of Nebraska, 2015

Supervisor: Georgette Kanmogne, Ph.D., MPH
Human Immunodeficiency Virus (HIV-1) infection often results in blood-brain barrier
(BBB) dysfunction and central nervous system (CNS) impairment. Since most viral
strains that cross the BBB and enter the CNS are macrophage-tropic and use the C-C
chemokine receptor type-5 (CCR5) to enter and infect target cells, we hypothesized that
CCR5 plays a major role in monocytes-endothelial interactions and HIV-induced BBB
dysfunction. Because the cytoskeleton is responsible for cellular morphology and
motility, we further hypothesized that HIV-induced monocyte-endothelial interactions and
transendothelial migration involve cytoskeletal changes and that CCR5 blockers would
also affect these changes. To this end we used two small molecule CCR5 antagonists,
TAK-779 and maraviroc (MVR), to evaluate the role of CCR5 on cytoskeletal changes in
HIV-1-infected monocytes following monocyte-endothelial interactions. We found that
HIV-1 infection of monocytes resulted in the upregulation of cytoskeletal-associated
proteins following monocyte-endothelial interactions. Proteins identified included Rac1,
ERK1/2, and cortactin. Rac1 phosphorylation at serine 71 (s71) was upregulated in our
in vitro studies and this upregulation was validated in analyses of ex-vivo brain tissues of
HIV-1-infected humans. We next examined the effect of MVR treatment on HIV-1induced BBB injury and CNS infection in vivo using humanized mice. We hypothesized
that MVR treatment could diminish HIV-induced BBB injury and CNS infection. HIV-1
infection resulted in decreased expression of the tight junction proteins claudin-5 and
ZO-2 in the animals’ brain blood vessels and MVR treatment partially attenuated these

	
  

	
  

	
  

	
  

changes. Furthermore, our data showed that MVR enters the CNS and MVR treatment
reduced viral loads in brain tissues. In conclusion, this study suggests that blocking
CCR5 can diminish HIV-1-induced cytoskeletal changes, diminish BBB injury and CNS
infection.
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1.1 Background
Since its discovery in the early 1980’s, the human immunodeficiency virus-1 (HIV-1) has
infected nearly 78 million people and killed approximately 39 million people [1].
Untreated HIV-1 infection typically results in acquired immune deficiency syndrome
(AIDS). AIDS is diagnosed when a patient’s CD4+ T-cell count drops to 200 cells/mm3 or
fewer or the patient presents with opportunistic infections and cancers, such as
Pneumocystis jirovecii pneumonia, Kaposi's sarcoma, and progressive multifocal
leukoencephalopathy [2, 3]. An estimated 35 million people are currently living with
HIV/AIDS. Although prevalent worldwide, Sub-Saharan Africa bears the heaviest
burden, with 71% of people living with HIV/AIDS located in this region [1].
HIV-1 is a lentivirus of the retroviridae family [4]. It infects cells of the immune
system that express the CD4 receptor and/or the chemokine receptors CC chemokine
receptor 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR-4), such as T-cells and
monocytes/macrophages [4]. After HIV-1 enters the cell, the viral capsid uncoats, which
allows for the release of viral RNA and proteins into the cytoplasm [4]. The viral RNA is
then reverse transcribed into complementary DNA, forms the preintegration complex,
and translocates to the nucleus, where the viral DNA is integrated into the host’s DNA
[4]. Once integrated, the virus hijacks the host cell’s transcriptional machinery to
synthesize viral RNA [4]. The viral RNA is then exported to the cytoplasm and translated
into viral proteins [4]. Following translation, both the viral RNA and proteins are
translocated to the plasma membrane, where they are packaged into immature virions
[4]. The virions bud off the cell and are released into the extracellular fluid [4]. Once
released, the virions undergo maturation and become infectious. These mature virions
then go on to infect other cells [4].
The HIV-1 genome is approximately 9749 nucleotides in length consisting of 9
open reading frames (ORFs) encoding viral proteins [5]. The ORFs encode three
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structural proteins: Gag, Pol, and Env (gp160); two regulatory proteins: transactivator of
transcription (Tat) and Rev; and four accessory proteins: viral infectivity factor (Vif), viral
protein R (Vpr), viral protein U (Vpu), and negative factor (Nef) [5]. Gag is proteolyzed
into the matrix protein p17, the capsid protein p24, two spacer peptides, the
nucleocapsid proteins p7, and p6 [5]. Pol is proteolyzed into reverse transcriptase (RT),
RNase H, integrase, and HIV-1 protease [5]. The Env protein gp160 is proteolyzed into
gp120 and gp41 [5].
Before the advent of antiretroviral therapy (ART) or highly active antiretroviral
therapy (HAART) HIV-1 was almost always fatal. In developed countries, ART has
transformed HIV-1 from a fatal infection into a chronic, lifelong illness. The first approved
antiretroviral was the nucleoside analog reverse-transcriptase inhibitor (NRTI)
Zidovudine/azidothymidine (AZT, Retrovir; ViiV healthcare, Brentford, London, UK) in
1987, followed shortly by several other NRTIs [6]. In 1996 two new classes of ART were
introduced, the non-nucleoside reverse transcriptase inhibitors and protease inhibitors
[6]. Two more classes of drugs were introduced in the 2000s, entry/fusion inhibitors and
integrase inhibitors [6]. The success of ART has not come without its drawbacks,
including increases in cardiovascular and metabolic diseases [7].
One of the biggest impediments to effective treatment and HIV eradication is the
presence of viral reservoirs, such as the brain and lymphoid tissues. HIV enters the
brain as early as 8-14 days post-infection, before most people are aware they have been
infected [8]. Infection of the brain is often associated with neurocognitive impairment [9].
Poor central nervous system (CNS) penetration of many antiretroviral drugs allows for
continued HIV replication in the brain [10]. Antiretroviral drugs that are able to prevent
HIV entry into the brain and reduce the CNS viral load will be important in eliminating
viral CNS reservoirs, which could help cure HIV-1.
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1.2 CCR5
CCR5 is a member of the beta chemokine receptors found macrophages, dendritic cells,
and memory T cells in the immune system; endothelium, epithelium, vascular smooth
muscle and, fibroblasts; and microglia, neurons, and astrocytes in the central nervous
system [11]. The CCR5 gene is located on chromosome 3p21 and consists of 3 exons
and 2 introns [12, 13]. Two promoters, one upstream and one downstream of exon 1,
regulate its transcription [13]. The downstream promoter contains consensus TATA
elements and potential binding sites for several transcription factors, such as signal
transducers and activators of transcription (STAT), nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB), and activator protein 1 (AP-1) [13, 14]. CCR5 is a
G-protein coupled receptor (GPCR) consisting of 352 amino acids, and like all GPCRs is
comprised of 7 transmembrane domains with three extracellular loops and four
intracellular loops [15, 16]. The N-terminal domain is extracellular, whereas the Cterminal domain is intracellular and the transmembrane domains appear to be arranged
in a cluster instead of linear [17, 18]. CCR5 endogenous ligands are chemokine (C-C
motif) ligand 3, 4, and 5 (CCL3, 4, and 5) [19-21].
Although the exact ligand-binding mechanism is unknown, the proposed
mechanism involves the ligand first binding to the N-terminal domain followed by binding
to the first and second extracellular loops [22]. The amino terminus activates the
receptor via interactions with the transmembrane domains and the second extracellular
loop is responsible for determining ligand specificity [22]. Following ligand binding and
receptor activation, the receptor undergoes a conformational change and the receptorbound G protein, Gi, Go, or Gq, dissociates from the receptor [23-28]. Activation of
CCR5 can promote Ca2+ release and activation of phosphatidylinositol-4,5bisphosphate 3-kinase (PI3K), mitogen-activated protein kinases (MAPK), focal
adhesion kinase (FAK), proline-rich tyrosine kinase 2, extracellular signal-regulated
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kinase 1/2 (ERK1/2), stress-activated protein kinase/	
  c-Jun N-terminal kinase (JNK), Rho
GTPase, and protein kinase B (PKB) [29-33]. Following ligand binding, the receptors are
internalized, which prevents further activation [34].
The major role of CCR5 is the recruitment and chemotaxis of immune cells to
sites of inflammation [22]. Many other functions have been proposed. CCR5-deficient
mice develop normally, but appear to have a partial defect in macrophage function [35].
Furthermore, these mice have an enhanced delayed-type hypersensitivity reaction and
increased humoral responses to T cell-dependent antigenic challenge [35]. This
suggests that CCR5 has a role in down-modulating T cell-dependent immune response.
Interactions of CCR5 and CCL5 produce an anti-apoptotic signal in macrophages during
viral infection [36]. It may also play a role In T-cell activation [37]. A 32 amino acid
deletion mutation on exon 1 (CCR5Δ32) leads to decreased expression and dysfunction
of CCR5 receptor [14, 38, 39].
CCR5 is known for its role as a co-receptor for HIV and is important in HIV
transmission and disease progression. Individuals with the CCR5Δ32 mutation have
delayed HIV-1 disease progression or are resistant to HIV-1 infection [14, 38-41].
Besides HIV-1, CCR5 can play a role, either beneficial or harmful, in other viral
infections. CCR5 is critical for the survival of mice infected with West Nile virus (WNV)
and humans with the CCR5Δ32 mutation appear to have a higher risk of death during
WNV infection [42, 43]; absence of the CCR5 gene is also associated with increased
prevalence and severity of tick-borne encephalitis [44]. On the other hand, absence of
CCR5 may provide protection against smallpox infection and the bubonic plague [45]. In
addition to viral infections, due to its role in chemotaxis and inflammation, CCR5 is
suspected to play a part in several types of cancer. And as with viral infections this can
be either beneficial or harmful. Strong expression of CCR5 is associated with nonmetastatic colorectal cancer and weak CCR5 expression is associated with lymph node
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metastasis and advanced disease [46]. Stromal cells that express CCR5 have been
shown to increase pulmonary metastasis [47]. Interaction of CCL5 and CCR5 can
enhance the migration of chondrosarcoma cells and human oral cancer cells [48, 49]. In
gastric cancer, CCL5/CCR5 is highly expressed in the cancers with lymph node
metastasis [50]. Furthermore, CCL5/CCR5 was shown to promote proliferation of gastric
cancer cells and increase the tumor burden in mice transplanted with gastric cancer cells
[51].
1.3 HIV Entry
HIV cellular entry is a complex, multiple step process. Entry begins by the virus binding
to the cell surface [52]. This can be facilitated by attachment factors such as heparin
sulfate or dendritic cell–specific intercellular adhesion molecular 3-grabbing non-integrin
(DC-SIGN), although they are not required and differ between cell type and viral strain
[52]. Attachment occurs through non-covalent interactions with the HIV Env and the
attachment factor, and accelerates the interactions between the virus and the cell by
bringing Env closer to CD4 and the co-receptor [52]. Attachment is often the rate-limiting
step of viral infection [52]. Entry involves Env binding to two cellular receptors in a
sequential pattern. Env is composed of trimers of two subunits: gp120 and gp41 [52].
The gp120 subunit, which is responsible for the receptor and co-receptor binding,
contains five conserved domains (C1-C5) and five variable loops (V1-V5) [52]. The gp41
subunit, which is responsible for viral fusion, is a transmembrane protein composed of
an N-terminal fusion peptide followed by N and C terminal heptad repeat (HR) regions
and lastly a membrane-proximal external region (MPER) [53].
The initial binding step in HIV entry involves gp120 binding to CD4 [54]. CD4 is
an immunoglobulin superfamily member found on the surface of immune cells such as T
helper cells, macrophages, and dendritic cells [55]. The primary function of CD4 is to
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assist the T-cell receptor in communicating with antigen-presenting cells, but also
appears to enhance Fc region of IgG responses in other cell types [56]. CD4 contains
four immunoglobulin domains (D1-D4), with D1 and D3 resembling immunoglobulin
variable domains and D2 and D4 resembling immunoglobulin constant domains [57]. In
T-cell-antigen presenting cell binding, the D1 domain of CD4 interacts with the β2domain of MHC class II molecules [57]. In HIV entry, gp120 binds to CD4 via the CD4
binding site, resulting the rearrangement of V1/V2, which in turn causes the
rearrangement of V3 [58]. Rearrangement of the V3 loop leads to exposure of the coreceptor-binding site and positions the stem for co-receptor binding and exposure of the
gp41 N-HR region [52]. Formation of the bridging sheet, the second co-receptor-binding
site, also occurs during CD4 binding [59]. The bridging sheet is a four-stranded beta
sheet comprised of two beta sheets from the inner domain and two beta sheets from the
outer domain of gp120 [60].
Following V3 rearrangement and formation of the bridging sheet, co-receptor
binding occurs [52]. The two most common co-receptors are the chemokine receptors
CCR5 and CXCR4, with CCR5-using viruses (R5 viruses) being the predominant forms
during the early stages of infection, while CXCR4-using viruses (X4 viruses) are
associated with disease progression and AIDS [52]. The N-terminal domain and the
extracellular loops of the co-receptors are important for gp120 binding [59]. During coreceptor binding, the V3 loop of gp120, which had previously undergone rearrangement
during CD4 binding, binds to the second extracellular loop (ECL2) of the co-receptor
[59]. Following gp120 binding to the ECL2, four sulfated tyrosine residues, at positions 3,
10, 14, and 15, in the N-terminal domain of the co-receptor interact with the base of the
V3 loop and the bridging sheet [59].
Following co-receptor binding, the viral membrane fuses to the host cell
membrane. The viral Env, a class I fusion protein, mediates viral fusion using a trimer-of-
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hairpins pathway of membrane fusion [61]. When gp120 binds to CD4, gp41 undergoes
a conformational change to its pre-hairpin orientation [59]. In this state, a trimer of
helices is formed from the N-terminal peptides. The C-terminal helices remain attached
to the viral membrane [62]. The rearrangement of the N-terminal peptides into a trimer
allows the fusion peptide to be inserted into the cell membrane [62]. Once binding to the
co-receptor occurs, gp120 dissociates from the viral Env, freeing gp41 and allowing it to
engage with the cellular membrane [62]. During fusion gp41 undergoes further
conformational change to form the hairpin fusion-active state, called the six-helix bundle
(6-HB), in which the C-terminal HRs wrap around the N-terminal HRs in an antiparallel
manner [63]. Each of the N-terminal HRs contains a hydrophobic deep pocket which
helps to stabilize 6-HB formation and membrane fusion [64]. The 6-HB brings the viral
membrane in close proximity to the cellular membrane resulting in fusion and the viral
core entrance into the cell [65, 66]. HIV-1 entry is summarized in Figure 1-1.
Although it was previously thought that HIV-1 only enters the cell by fusing with
the plasma membrane, it is now known that it can enter the cell via endocytosis [67].
HIV-1 has been shown to fuse with endosomes [68, 69]; and increasing the endosomal
pH increases HIV-1 fusion and infection [70]. Inhibition of clathrin- and dynamindependent endocytosis or micropinocytosis reduces HIV-1 infection [71, 72]. Endocytic
entry offers several advantages, such sheltering HIV-1 from antibodies and inhibitors
targeting intermediate conformations of Env [71].
1.4 HIV tropism
Viral tropism is determined by co-receptor binding. Most clinically relevant strains use
CXCR4 or CCR5 [73]. However, it has been demonstrated that some HIV strains can
use other co-receptors. These co-receptors include CCR3, which has been implicated in
the infection of microglia [74, 75], CCR2b [76], and CCR8 [77]. These other co-receptors
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do not appear to play a major role in HIV-1 pathogenesis [78]. CCR5 appears to be the
main co-receptor in HIV-1 transmission and pathogenesis, with viruses that use CXCR4
occurring during the later stages of infection [79, 80]. R5 viruses are typically
macrophage-tropic (M-tropic) viruses due to their ability to infect macrophages, in
addition to being able to infect CD4+ T-cells [81]. However, some R5 viruses cannot
efficiently infect macrophages [79, 82, 83]. R5 viruses do not normally induce syncytia
and are typically the main source of viral reservoirs [79]. On the other hand, X4 viruses
are typically T-tropic and mainly infect CD4 T-cells [81]. However, some X4 viruses can
also infect macrophages [84]. X4 viruses normally induce syncytia and can directly kill
CD4 T-cells [85]. Viruses that can use both co-receptors are called dual-tropic viruses
[86].
Co-receptor usage is determined by genetic variations in the viral Env, with the
V3 loop playing a major role [86]. Therefore, genotypic methods can be used to predict
viral tropism. The 11/25 rule is a genotyping method for predicting co-receptor use [87].
This rule states that a virus is more likely to be X4–tropic if the amino acid residues at
positions 11 and 25 are arginine, histidine, or lysine, all positively charged amino acids
[87]. While the 11/25 rule is highly sensitive for predicting syncytia-inducing viruses
(~96%), it is not as sensitive for predicting X4-tropic viruses (~58%) [87]. However, this
rule is a good clinical predictor of disease progression [88, 89]. Treatment experienced
patients had significantly lower CD4 counts and poorer immunological restoration while
receiving ART when they were predicted to have X4-tropic viruses using the 11/25 rule
[88, 89]. In general, the V3 loop of R5 viruses have a net charge of +3 to +5, whereas
the V3 loop of X4 viruses have a net charge of +7 to +10 [87]. Interactions with the coreceptor N-terminal domain, in general, is necessary for R5 viruses [90]; whereas X4
viruses interact with the co-receptor ECL2 domain, with little-to-no interactions with the
N-terminal domain [91, 92]. The electrostatic charge of the virus also plays a role in
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determining tropism. The N-terminal domain of CCR5 is negatively charged, containing
three acidic amino acids and the sulfated tyrosine residues, and can interact with the
positively charged bridging sheet of gp120 [92]. The ECL2 domain of CXCR4 carries a
negative charge, containing five acidic amino acids, and can interact with the positively
charged V3 loop [92].
Clinically, viral tropism is determined phenotypically by the Trofile assay
(Monogram Biosciences, Inc., South San Francisco, CA) [93]. In this assay the viral Env
gene is amplified from plasma, cloned into a vector, and co-transfected with an Envdeficient HIV-1 genomic vector into HEK293 cells [94]. The HIV-1 particles are harvested
and used to infect U87:CXCR4 and U87:CCR5 cells [94]. The Env-deficient HIV-1
genomic vector carries a luciferase reporter gene, which will produce a signal in the
U87:CXCR4 cells when X4-tropic viruses are present or in the U87:CCR5 cells when
R5-tropic viruses are present [94]. If a signal is produced in both cell types, the virus is
considered to be dual-tropic [94]. Tropism is further confirmed by the use of inhibitors for
CCR5 or CXCR4 [93]. This assay is typically performed when a patient is being
considered for CCR5 antagonists or exhibiting virological failure with CCR5 antagonists
[93]. Earlier versions of the assay did not detect low levels of X4 viruses; it could fully
detect X4 variants present at 10% of the viral population, but only had a detection rate of
85% when X4 variants constituted 5% of the viral population [94]. However, a newer
version of this assay, with enhanced sensitivity, is able to detect X4 variants present at
0.3% of the viral population with 100% sensitivity [95].
1.5 History of HIV-1 entry inhibitors
The development of inhibitors to block the entry of HIV-1 had been a topic of interest for
many years before approval of enfuvirtide (ENF, Fuzeon; Hoffman-La Roche, Nutley,
NJ, USA) in 2003 by the Food and Drug Administration (FDA) [96]. Enfuvirtide binds to
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the viral gp41 to prevent the formation of the entry pore [96]. This would remain the only
entry inhibitor available until the FDA approval of maraviroc (MVR; Selzentry, ViiV
Healthcare). MVR is unique in its mechanism of action compared to other antiretroviral
agents in that it targets the host cell instead of the virus [97].
Some of the earliest attempts to block the entry of the virus were through the
development of soluble CD4 (sCD4) molecules [98]. These molecules lack the
transmembrane and cytoplasmic domains of CD4 but are able to bind to viral gp120 and
prevent it from binding to the cellular CD4 [98]. In vitro they were able to inhibit HIV-1
entry at high doses [98]. However, in clinical trials sCD4 molecules were not effective in
decreasing the viral loads of HIV-1-infected patients [98]. The small molecule gp120
inhibitors BMS-378806 and BMS-448043 were discontinued during clinical trials [99].
BMS-626529 and its prodrug BMS-663068, two small molecule gp120 inhibitors, are
currently in phase II clinical trials and have demonstrated good efficacy and safety [100].
Ibalizumab is a monoclonal antibody that binds to CD4 and has completed phase I and II
clinical trials [101]. Ibalizumab does not prevent gp120 binding to CD4, but can decrease
the flexibility of CD4 and inhibit gp120 access to the co-receptors [101]. Other agents,
often called fusion inhibitors, have been developed that prevent fusion of gp41 to the
cellular membrane. ENF, a 36 amino acid synthetic peptide corresponding to the HR2
region of gp41, prevents the association of HR1 and HR2 [102]. Due to its low oral
bioavailability, ENF must be injected subcutaneously twice daily [103]. For this reason
ENF is often used only for salvage therapy [96].
In 1996 the HIV-1 co-receptors, CCR5 and CXCR4, were discovered and
became ideal candidates for the development of drugs blocking HIV-1 infection [99].
AMD3100, a small molecule CXCR4 antagonist, was one of the first co-receptor
inhibitors identified, and displayed antiviral activity against X4-tropic strains [104].
Further development for the treatment of HIV-1 infection was discontinued due to lack of
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efficacy and cardiac abnormalities [105]. However, AMD3100 found a new life for the
treatment of non-Hodgkin's lymphoma [106]; and is used to mobilize hematopoietic stem
cells [106]. Of particular interest as a drug target is CCR5, as it was previously shown
that its natural ligands CCL3, CCL4, and CCL5 could block HIV-1 infection [107]. Nterminal domain modifications of CCL5 have been developed to enhance the
antiretroviral activity of natural CCL5, including MET-RANTES and AOP-RANTES [108,
109]. Several small molecule CCR5 antagonists have been discovered and four have
made it to at least phase II clinical trials: aplaviroc, vicriviroc, INCB009471, and
maraviroc [110]. Aplaviroc displayed good efficacy in clinical trials, but development was
terminated due to hepatotoxicity in phase IIb and III trials [111]. Development of
vicriviroc was discontinued during phase III clinical trials due to a lack of efficacy [110].
INCB009471 showed good efficacy in a phase II study and also has a half-life of 60
hours, making once-a-day dosing an option [110]. However, the company developing
this drug decided to discontinue further studies [110]. The FDA approved MVR in 2007
for use in treatment-experienced HIV-1-infected individuals with R5-tropic infection, and
it was subsequently approved for treatment-naïve HIV-1-infected individuals with R5tropic infection [112].
1.6 The CCR5 inhibitor Maraviroc
MVR, originally called UK-427,857 (empirical formula: C29H41F2N5O), was developed by
Pfizer in their efforts to discover small molecule CCR5 ligands [113]. MVR binds
allosterically to the CCR5 receptor on the cell surface and prevents binding of the viral
gp120 to the receptor [114]. MVR has a molecular weight of 513.67 g/mol. It is
moderately lipophilic, with a distribution constant at pH 7.4 (log D7.4), and is a weak
base, with a logarithmic acid dissociation constant (pKa) of 7.3 [97, 115]. It is highly
soluble across the pH range of 1 to 7.5 [112]. MVR is bound to plasma proteins at 76%
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[97]. The half-life of MVR is approximately 16 hours and maximum plasma
concentrations occur 2 hours after dosing [115]. For a 300 mg/kg dose, the maximum
concentration in plasma is 800 ng/g and exposure is 4497 ng*h/l [115]. The absolute oral
bioavailability of 300 mg MVR is 33% [115]. MVR is widely distributed throughout the
body, with detectable levels being found in the seminal plasma, vaginal tissue and
cervicovaginal fluid, rectum, and cerebrospinal fluid (CSF) [112, 116-125].
MVR is metabolized by cytochrome P450 (CYP) 3A4 (CYP3A4) and CYP3A5
and is a substrate for P-glycoprotein-1 (Pgp1) [112]. In the plasma, MVR remains largely
unchanged, accounting for 42% of the circulating forms [115]. The most abundant
metabolite present in the plasma is a secondary amine product of N-dealkylation [112].
MVR is excreted mainly through feces (76.4%), but also can be excreted through urine
(19.6%) [115]. Most of the excretion through feces occurs within 96 hours and most of
the excretion through urine occurs within 36 hours [115].
A Phase II trial in asymptomatic humans infected with R5-tropic HIV-1 receiving
300 mg/kg twice daily of MVR showed a decrease in HIV-1 RNA levels of 1.6 log10
copies/ml compared to a decrease of 0.02 log10 copies/ml in infected humans receiving
placebo [126]. The efficacy of MVR was further confirmed in a pair of phase III trials, the
Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced
Patients (MOTIVATE) 1 and 2 [127]. Eligible subjects had evidence of resistance to
drugs from three antiretroviral classes or were triple-class experienced, had plasma HIV1 RNA levels >5,000 copies/mL, and exclusively had R5 virus at screening [127].
Patients received oral MVR or placebo once or twice daily, with doses being adjusted for
the other drugs in the patient’s ART regimen [127]. Treatment with MVR decreased viral
RNA load by week 48, compared to placebo, with a viral RNA load decrease of −1.84
log10 copies/ml in patients receiving MVR compared to −0.79 log10 copies/ml in patients
receiving placebo [127].
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In addition to reducing viral load, MVR has been shown to be involved in immune
restoration during HIV infection. In the MOTIVATE trials CD4 cell counts increased to
124 cells/mm3 in the MVR arms compared with 61 cells/mm3 in the placebo arms [127].
This was true even after adjusting for the greater virologic potency of MVR-containing
regimens [128]. Short-term MVR treatment of patients with persistent virological failure
resulted in increased levels of CD4+ and CD8+ T-cells and was positively correlated with
improved antiviral activity [129]. HIV-1-infected patients who received MVR
intensification therapy had accelerated recovery of CD4+ T cell counts and maintained
higher CD4+ T cell counts after MVR discontinuation [130]. In patients with suppressed
viremia MVR treatment was associated with modest increases in CD4+ and CD8+ T cell
counts and reduction in the percentages of regulatory T cells (Tregs) [131]. Reductions
in Tregs with MVR treatment have been shown in other studies of treatment-naïve
patients and can become evident as early as 8 days after treatment initiation [132].
MVR has been successfully used in clinical settings, resulting in decreased viral
loads and increased CD4 cell counts [133, 134]. Treatment failure is often due to the
outgrowth of previously undetectable X4-tropic viruses [135, 136]. In addition, MVR has
also been suggested as a candidate for pre- or post-exposure prophylaxis [137-140], for
use in dual therapy regimens (protease inhibitor and nucleoside/nucleotide reverse
transcriptase inhibitors sparing regimens) [141-144], and in the treatment of immune
reconstitution inflammatory syndrome [145, 146]. Outside of HIV-1 infection, MVR has
also shown efficacy in the treatment of cancer by preventing metastasis of cancer cells
[51, 147, 148], graft-versus-host disease by inhibiting lymphocyte trafficking [149, 150],
and pulmonary arterial hypertension by reducing inflammation [151].
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1.7 The Blood-Brain Barrier (BBB)
The BBB acts as a barrier between peripheral circulation and the CNS [152]. Functions
of the BBB include controlling the influx and efflux of substances into and out of the
brain, regulating ion homeostasis, and immune surveillance [152]. The BBB is composed
of brain microvascular endothelial cells (BMVECs), basement membranes, pericytes,
and astrocytic end-feets (Figure 1-2) [152]. BMVECs form a monolayer and provide a
continuous cellular barrier between the blood and the interstitial fluid; they are involved
in the transport of micronutrients and macronutrients, receptor-mediated signaling,
leukocyte trafficking, and osmoregulation [152]. Astrocytes are glial cells that encircle the
endothelium, provide a cellular link to the neurons, and promote the formation of
endothelial tight junctions (TJs) [152]. They may also be involved in the maintenance of
BBB tightness and function [152]. On the brain side of the barrier there is a basement
membrane composed of fibronectin and laminin that is embedded with pericytes, which
partially wrap the endothelial cells [152]. Pericytes help stabilize the BBB and regulate
blood flow and BMVEC proliferation [152]. Pericytes also display macrophage-like
activity such as taking up small and soluble molecules by pinocytosis to clean the
extracellular fluid of the BBB and act as phagocytes in response to inflammation [153].
BMVECs are connected together via adherent junctions, gap junctions, and TJs
proteins. TJs are responsible for the barrier function of these cells (Figure 1-3) [154]; and
include the integral membrane proteins: occludin, claudins, junctional adhesion
molecules (JAMs); and the accessory proteins: zonula occludens (ZOs) [154]. Occludin,
a 65-kDa protein, detected in the cellular margins of BMVECS, is involved in TJ
stabilization and optimal barrier function, as well as signal transduction [154]. While
occludin does not appear to be essential for the formation of TJs, decreased expression
is associated with BBB dysfunction [154]. Located in a similar membrane area as
occludin, claudins are a large family of proteins, 20 to 27 kDa, comprising 27 members
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with high sequence similarities in humans [155, 156]. Claudins can interact with each
other in either a homophilic or heterophilic manner and are responsible for forming the
primary seal of TJs [156]. Claudin-5 is the dominant claudin in BMVECs, although
claudins-1, 3, and 12 are also expressed [156]. The JAM family consists of JAM-A, B,
and C; they form homotypic cell-cell contacts between endothelial cells and regulates
cell polarity, BBB stability, and leukocyte transmigration through BBB [157]. ZOs are
membrane-associated guanylate kinase proteins containing multiple binding domains for
protein-protein interactions [154]. The ZO proteins connect the transmembrane TJ
proteins to the actin cytoskeleton [154]. In the BBB the most highly expressed ZO
proteins are ZO-1 and ZO-2 [154].

1.8 HIV-associated neurocognitive disorders (HAND)
1.8.1 Pathogenesis of HAND
HAND is a spectrum of neurological disorders that occurs as the result of HIV infiltration
into the brain and injury to brain cells, including neurons [158]. HAND is classified into
three categories, depending on disease severity: asymptomatic neurocognitive
impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia
(HAD) [155]. Patients with ANI display acquired impairment in cognitive functioning in at
least two ability domains during neuropsychological testing, but do not have impairment
in activities of daily living (ADLs) and any delirium or dementia [155]. Patients with MND
display mild and acquired impairment in at least two cognitive ability domains during
neuropsychological testing and at least some mild impairment in their ADLs, but have no
delirium or dementia [155]. HAD is the most severe form, with patients displaying
acquired, moderate-to-severe cognitive impairment involving at least two ability domains
during neuropsychological testing, with accompanying motor and behavioral
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impairments, marked impairments in their ADLs, and dementia [155]. Although the
prevalence of HAD has decreased with the introduction of ART, the levels of ANI and
MND have increased [155]. The CNS HIV Antiretroviral Therapy Effects Research
Group, the largest study to date examining HIV cognitive impairment, showed that 52%
of HIV-seropositive patients had cognitive impairment [159]. Other studies estimate that
20 to 70% of HIV-1-infected individuals with access to antiretroviral therapy have
neurocognitive deficits [160-166]. This increased prevalence of HAND can be partially
explained by the increased lifespan of HIV-1-infected patients [158].
HIV-1 neuropathogenesis results from a combination of cellular and viral factors
[167]. Current knowledge based on in vivo and in vitro studies provides a general outline
of how HIV-1-CNS infection and the eventual progression to HAND occur: HIV-1infected monocytes and macrophages infiltrate the brain and establish residence, as well
as productively infecting microglia, the resident immune cells of the brain (Figure 1-4)
[167]. The infected cells become activated and mount an immune response causing the
release of cytokines and chemokines. Infected cells also secrete viral proteins and toxic
factors [168]; and the combination of cytokines, chemokines, and viral proteins leads to
further activation of brain immune cells [168]. Although HIV-1 does not infect neurons,
the constant barrage of viral proteins and inflammatory molecules and toxic factors
results in encephalitis, neuronal injury, damage, and apoptosis, which eventually leads
to neurocognitive impairment [168]. The hallmark of chronic CNS inflammation during
HIV infection, termed HIV encephalitis (HIVE), is characterized by the presence of
multinucleated giants cells, microgliosis, microglial nodules, astrogliosis, and neuronal
loss [155].
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1.8.2 The blood-brain barrier and HAND
BBB alterations occur early after peripheral HIV-1 infection occurs [169]. HIV-1 is
thought to enter the brain via infiltration of HIV and infected cells through the BBB,
known as the “Trojan horse” mechanism [170]. HIV-1 virions and viral proteins, such as
gp120, Tat, Nef, and Vpr induce BBB inflammation and dysfunction, and this is
associated with increased expression and secretion of proinflammatory cytokines and
chemokines such as tumor necrosis factor alpha (TNFα), interleukin (IL)-6, IL-8, and
CCL2 by infected and/or activated cells [171, 172]. This results in damage to endothelial
cells, enabling further cellular infiltration [168]. Additionally, secretion of cytokines and
chemokines results in increased clustering of integrin receptors to facilitate monocyte
binding and increased expression of adhesion molecules to facilitate monocyte adhesion
[173].
Viral proteins that cause BBB damage and increase permeability include Tat,
gp120, and Nef [173]. These viral proteins can increase endothelial permeability by
decreasing the expression of claudins, ZO1, ZO2, and occludin [174-180]. Tat can
induce adhesion to the extracellular matrix via focal adhesions and can cause apoptosis
of BMVECs by the induction of caspases [177, 181]. Tat can also induce oxidative stress
by dysregulating nitric oxide production and decreasing the levels of intracellular
glutathione in BMVECs [177, 182]. Exposure of BMVECs to Tat results in upregulation of
matrix metallopeptidase-3 (MMP3), which in turn can further degrade occludins [175].
Exposure of BMVECs to gp120 can induce the passage of HIV across the BBB by
induction of adsorptive endocytosis [183-185]. Additionally, exposure of BMVECs to
gp120 can increase the expression of adhesion molecules such as intercellular adhesion
molecule-1 and vascular cell adhesion molecule-1, which increases monocyte adhesion
and migration across the BBB [186-188]. HIV-1 gp120 can also induce MMP2 and
MMP9 and decrease laminin in the BBB basement membrane [189]. Nef is expressed in
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astrocytes of HIV-1 patients, especially in patients with dementia [190], and increases
the sensitivity of astrocytes to hydrogen peroxide [191]. Like gp120, Nef can increase
MMP9 expression and induce BBB disruption [192].
1.8.3 Neurons and HAND
Once HIV-1-infected cells set up residence in the brain, a combination of viral
and cellular factors causes neuronal dysfunction, damage, and eventual neuronal death
[167]. Cytokines and chemokines, released from activated macrophages, microglia, and
astrocytes, are elevated in the brains and CSF of HAND patients [158]. These include
TNFα, IL-6, CCL2, CCL3, CCL4, and CCL5 [155]. These cytokines and chemokines can
induce monocyte/macrophage migration and accumulation in the CNS [155]. There is
evidence that TNFα, more than HIV-1 infection itself, is one of the major inducers of
monocyte migration into the CNS [193]. In addition, TNFα can cause direct neuronal
damage [158, 194]. Besides cytokines and chemokines, other cellular factors involved in
HAND include neurotoxins such as quinolinic acid and nitric oxide, which can be
neurotoxic when produced in excess [155].
Furthermore, several HIV-1 proteins shed from infected cells, such as Nef,
gp120, and Tat, are known to be neurotoxic [155]. Gp120 can bind directly to N-methylD-aspartate receptor (NMDAR) and cause a lethal influx of calcium ions in neurons
[195]. Gp120 binds to CCR5 or CXCR4, without the presence of CD4, on neurons and
promotes apoptosis [196, 197]. Gp120 has also been associated with oxidative stress
[198, 199]. Similarly, Tat can activate NMDAR to cause a toxic influx of calcium ions and
promote oxidative stress in neurons [200, 201]. Tat can also activate caspases, cause
mitochondrial dysfunction, and induce unfolded protein response leading to apoptosis
[202]. Gp120, Tat, and Nef can upregulate inflammatory molecules to cause neuronal
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dysfunction and death [155]. These include MMPs, TNFα, IL-6, nitric oxide, and CCL5
[155].
1.8.4 Monocytes/macrophages in HAND
Monocytes and macrophages play a major role in the pathology of HAND. HIV-1infected monocytes can traverse the BBB, and macrophages are the principal HIV-1infected cell type in the brain [203, 204]. Even with ART, monocytes/macrophages often
remain infected and constitute long-term viral reservoirs. In fact, HIV-1 DNA levels in
monocytes is associated with persistent HAND and peripheral infection of monocytes is
correlated with HAND in ART-treated individuals [205]. Furthermore, the accumulation of
macrophages in the CNS appears to be a more accurate predictor of HAND than CNS
infection itself [206].
Monocytes can be categorized into three main subsets: CD14++CD16- (high
CD14 expression, no CD16 expression), CD14++ CD16+ (high CD14 expression, low
CD16 expression), and CD14+CD16++ (low CD14 expression, high CD16 expression);
also known as classical resting monocytes, intermediate monocytes, and non-classical
activated monocytes, respectively [207]. Typically the non-classical CD16++ monocytes
only represent 5-10% of the total monocyte population [207]. However, the population of
these cells can expand to approximately 40% in HIV-1-infected individuals and higher
amounts are found in the brains of patients with HIV-1 encephalopathy [207, 208]. Nonclassical activated monocytes become infected with HIV-1 more easily and support
increased levels of viral replication [207]. Furthermore, they are able to migrate across
the BBB more efficiently compared to their classical counterparts [207]. These studies
provide evidence of the importance of monocytes in HIV-1-infection.

	
  

	
  

	
  

	
  

21	
  	
  

1.8.5 Mouse models of HAND
Mouse models have become a tool in understanding and treating HAND. These models
have several advantages compared to other models of HAND, such as SIV-infected
rhesus macaques; including the ease of handling, relative low cost, and well-established
and easy-to-use methods for manipulating the mouse genome [209]. Mouse models to
study HAND include transgenic mice, in which mice are genetically modified to express
HIV-1 genes. In these models HIV expression can be ubiquitous or tissue/cell-specific.
Once such model is the Tg26 mouse line, in which mice carry an HIV-1 construct
containing a 3.0-kb deletion of the gag-pol region in the pNL4-3 proviral genomic
construct [210]. These mice show expression of HIV-1 mRNA in skin, skeletal muscle,
kidneys rain, eye, gastrointestinal tract, spleen, and thymus. Another transgenic mouse
model involves the insertion of the viral Tat or Env gene into the mouse genome under
the control of a glial fibrillary acidic protein (GFAP) promoter, resulting in gp120 or Tat
protein expression by brain astrocytes [209]. Other transgenic models have been
developed for HIV-1 gene expression in immune cells, macrophages, and podocytes
[210].
More recently, humanized mouse models have become prevalent. Humanized
mice are immune deficient mice reconstituted with a human immune system, allowing for
long-term chronic HIV-1 replication [209]. One such mouse model involves the
engraftment of non-obese diabetic, severe combined immunodeficient, IL2 receptor
gamma chain deficient (NSG) mice with human peripheral blood lymphocytes (PBL)
[209]. These mice become engrafted rapidly with human immune cells, with particularly
strong T cell engraftment [209]. This model allows for a rapid and efficient method for
studying HAND. NSG mice reconstituted with CD34+ human hematopoietic stem cells
from human fetal liver allows for chronic HIV-1 infection, and subsequently long-term
studies. These mice develop a near-complete human immune system by 20-22 weeks of
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age [211]. Limitations of these humanized mice include variable levels of human cell
engraftment [212]. This can affect the pathology seen in the mice during HIV-1 infection.
In addition, the mice have incomplete peripheral immunopathology, due to a lack of
human stromal elements [212].
1.9 Study hypothesis
Most HIV strains that enter the CNS are R5-tropic [213, 214]. Studies in our laboratory
have previously shown that human brain microvascular endothelial cells (HBMEC)
express CCR5 and implicate CCR5 in HIV-1-induced BBB damage [179, 215]. CCR5
antibodies diminished HIV-1-induced activation of STAT1 and STAT3 and prevented
HIV-1-induced monocyte adhesion and migration in an in vitro BBB model [215]. HIV-1
activates STAT1 signaling in endothelial cells, which induces the transcription and
expression of proinflammatory cytokines and downregulates the expression of TJ
proteins [216]. CCR5 antibodies prevented gp120-induced intracellular calcium release
[179]. MVR treatment of HIV-1-infected patients increased cerebral metabolite markers
of neuronal integrity [122]. In addition, HIV-1-infected patients on MVR containing
regimens showed a trend towards improvement in neurocognitive status and reduced
TNF-α concentrations in the CSF [217].
Given the role of CCR5 in HIV-1 infection and the fact that most HIV-1 strains
that cross the BBB, enter the CNS, and cause HAND are CCR5-tropic, we set out to
further elucidate the role of CCR5 in BBB dysfunction following HIV-1 infection and
monocyte/macrophages interactions with HBMEC. We hypothesized that CCR5 plays a
major role in monocytes-BBB communications and CNS entry. HIV-1 infection increases
monocyte adhesion and migration through the BBB, and this can be prevented by CCR5
neutralizing antibodies [215]. Because the cytoskeleton is responsible for cellular
motility, we hypothesized that HIV-1 would induce cytoskeletal changes in monocytes

	
  

	
  

	
  

	
  

following infection and monocyte-endothelial communications and that blocking CCR5
would prevent those changes. We further hypothesized that CCR5 inhibition could
reduce HIV-1-induced BBB damage and reduce viral loads in the brain. In the present
study we used a combination of in vitro and in vivo techniques to determine the role of
CCR5 in HIV-1-induced BBB injury and HAND.
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1.10 Figures

Figure 1-1: HIV-1 receptor and co-receptor binding. The viral Env is composed of
three gp120 and three gp41 subunits. Gp120 binds to CD4 on the cell surface, causing a
conformational change in the Env protein. This conformational change allows for coreceptor binding, which is partially mediated by the V3 loop of Env. Following coreceptor binding, the fusion peptide of gp41 inserts into the cell membrane, followed by
formation of the six-helix bundle and membrane fusion. CCR5 or CXCR4 antagonists
can inhibit co-receptor binding and subsequent HIV-1 entry.
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Figure 1-2: The blood-brain barrier structure. The blood-brain barrier consists of
vascular endothelial cells connected via tight junctions, which regulate the passage of
molecules across the barrier. Pericytes, which partially surround the endothelium on the
side of the brain, provides support to the vessels and regulate capillary blood flow. The
endothelial cells and pericytes are enclosed by a basement membrane. The basement
membrane is involved in vessel development, stability, and has a barrier function.
Astrocytic end-feets surround the endothelium and provide a connection to neurons.
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Figure 1-3: Molecular components of tight junctions and adherens junctions in the
BBB. Tight junctions are composed of claudins, occludin, and junctional adhesion
molecules at the cell surface, all of which mediates cellular contact. These molecules
bind to ZO-1 or ZO-2, which bind tight junctions to the actin cytoskeleton. Adherens
junctions are composed of VE-caderhin at the cell surface. VE-cadherin binds to a
complex of catenin proteins, which bind to the cytoskeleton.
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Figure 1-4: HIV-1 neuroinvasion. HIV-1 enters the brain via the migration of infected
monocytes through the blood-brain barrier. Once inside the brain, these cells
differentiate into perivascular macrophages. Infected macrophages release viral particles
that productively infect microglia and can also infect astrocytes, and proinflammatory
molecules and viral proteins, which can damage cells. HIV-1 infection causes damage to
the endothelium, which allows for the passage of more infected cells and viral particles.
Although, HIV-1 does not infect neurons its virions, viral proteins, and cellular factors can
induce neuronal injury and damage, resulting in HAND.
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Chapter 2
CCR5 antagonists diminish HIV-1 infection, HIV-1-induced
monocyte migration, and HIV-1-induced cytoskeletal changes in
monocytes during monocyte-endothelial interactions
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2.1 Background
Most HIV-1 strains that cross the BBB, enter the brain, and infect CNS cells use CCR5
to enter and infect target cells [213, 214]. HIV-1 infection is associated with increased
monocyte adhesion and migration through the BBB, during which the cellular
cytoskeleton undergoes major changes and reorganization [218, 219]. GPCRs, including
CCR5, are associated with cytoskeletal reorganization [220, 221]. In macrophages,
activation of CCR5 by its natural ligands CCL3, CCL4, and CCL5 induce actin
reorganization and lamellipodia formation, sheet-like membrane protrusions found at the
leading edge of motile cells [221]. CCR5 is able to bind to alpha-catenin, which is known
to function in cell–cell adhesion and can act as a connector that attaches the plasma
membrane-associated cadherin adhesion-complex to the matrix of the cellular
cytoskeleton in PM1 T-lymphocytes, a cell line susceptible to a wide variety of HIV
isolates [220].
Small molecule CCR5 antagonists, such as MVR and TAK-779 (TAK), have
become a new avenue for the treatment of HIV-1 infection [65]. Not only does MVR
prevent viral entry, but it has also been reported to have several immunological benefits,
including decreased migration of immune cells [222-225]. We therefore hypothesized
that CCR5 plays a major role in monocyte-brain endothelium interactions and HIV-1
entry into the CNS, and that CCR5 antagonists would diminish these effects. We also
hypothesized that HIV-1-induced monocyte-endothelial interactions and transendothelial migration involve cytoskeletal changes, and that CCR5 blockers would also
affect these changes. To test these hypotheses, we used a cytoskeleton phosphoantibody array to investigate changes in the expression and activation of cytoskeletonassociated proteins in monocytes following HIV-1 infection and endothelial interaction
(summarized in Figure 2-1 and 2-2). We further used CCR5 antagonists (TAK and MVR)
and CCR5 neutralizing antibodies to determine the role of CCR5 on HIV-1 infection of
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monocytes-derived macrophages (MDM), monocyte-endothelial interaction, and
cytoskeletal changes. In addition, we examined the expression of cytoskeletonassociated proteins in the brain tissues of HIV-1 infected individuals.
2.2 Materials and Methods
2.2.1 Cell culture
Human monocytes were obtained from HIV-1-, HIV-2, and hepatitis B-seronegative
donors undergoing leukopheresis by countercurrent centrifugal elutriation of
mononuclear leukocyte-rich fractions. Monocytes were re-suspended in complete
Dulbecco’s Modified Eagles Media (DMEM) containing 2 mM L-glutamine (Life
Technologies, Grand Island, NY, USA), 10% heat-inactivated human serum, 100 µg/ml
gentamicin, and 10 µg/ml ciprofloxacin (Sigma, St. Louis, MO). MDM were obtained from
monocytes by culture for 7 days in complete DMEM containing 1,000 U/ml macrophage
colony-stimulating factor. Every two days, half of the medium was removed and replaced
with fresh medium.
Primary human brain microvascular endothelial cells (HBMEC) were isolated
from the temporal cortex of brain tissue obtained during surgical removal of
epileptogenic cerebral cortex in adult patients, under an Institutional Review Boardapproved protocol at the University of Arizona (Tucson, AZ). Routine evaluation for von
Willebrand factor, Ulex europaeus lectin, and CD31 showed that cells were >99% pure.
Freshly isolated HBMEC were plated on collagen-coated flasks or culture plates and
cultured using DMEM/F12 media (Life Technologies) containing 10% fetal bovine serum
(Atlanta Biologicals, Flowery Branch, GA, USA), supplemented with 10  mmol/l Lglutamine (Life Technologies), 1% heparin (Thermo Fisher Scientific, Pittsburgh, PA,
USA), 1% endothelial cell growth supplement (BD Bioscience, San Jose, CA, USA), 1%
penicillin-streptomycin (Life Technologies), and 1% fungizone (MP Biomedicals, Solon,
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OH, USA). Cells at passage 2 to 4 were used for all studies. All cells were maintained at
37°C in 95% oxygen and 5% CO2.
2.2.2 Cell treatment and HIV-1 infection
Monocytes were infected with HIV-1ADA, a clade-B M-tropic viral isolate, at a multiplicity
of infection (MOI) of 0.01 and cultured overnight (12 hours). After the 12 hours culture,
monocytes were washed 3 times with PBS to remove free viral particles and used for coculture experiments. For experiments testing the effects of CCR5 antagonists,
monocytes and MDM were treated with 5 µM TAK or 5 µM MVR for 30 min prior to viral
exposure. Both TAK and MVR were obtained from the NIH AIDS Research and
Reference Reagent Program. All reagents were prescreened for endotoxin (<10 pg/ ml,
Associates of Cape Cod, Woods Hole, MA) and mycoplasma contamination (Gen-probe
II, Gen-probe, San Diego, CA).
2.2.3 Trans-endothelial electrical resistance (TEER)
For TEER measurements, HBMEC were seeded on gold-film electrode surface (Applied
BioPhysics Inc., Troy, NY) and cultured to confluence. Confluent HBMEC were exposed
to 5 to 20 µM of TAK or MVR; TEER live-recorded readings were made before and after
exposures. Controls consisted of non-treated HBMEC and cells treated with 0.1%
saponin as non-resistant control. To determine whether any effect of the CCR5 blockers
on the BBB was reversible, HBMEC were washed after 48 hours to remove TAK or MVR
and TEER live-recorded readings were made for an additional 20 to 24 hours.
2.2.4 Co-culture of monocytes with HBMEC
HIV-1-infected monocytes were added to confluent monolayers of HBMEC in 100-mm
culture plates (5 monocytes for each HBMEC) and co-cultured for 2 hours. Controls
consisted of mock-infected monocytes co-cultured with HBMEC, as well as infected and
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mock-infected monocytes not cultured with HBMEC. Following the 2-hour co-culture,
monocytes were harvested by washing the HBMEC monolayer 3 times with PBS.
Adherent HBMEC were checked by microscopy to ensure maximal removal of
monocytes before harvesting endothelial cells by scrapping. Each cell type was pelleted
by centrifugation at 3,000 rpm for 10 min followed by protein extraction.
2.2.5 Protein extraction and cytoskeleton antibody microarray
The Cytoskeleton-II protein arrays and all reagents used for protein microarray analysis
were from Full Moon Biosystems (Sunnyvale, CA), except Cy3-conjugated streptavidin,
which was from GE Healthcare Life Sciences (Piscataway, NJ). Each Cytoskeleton-II
protein array contained 141 well-characterized phosphorylated antibodies of the
cytoskeletal pathway and corresponding total antibodies. To ensure reliability and
consistency of results, each array included 6 replicates of each antibody and phosphoantibody. Additional controls on each array included 6 positive controls consisting of Cy3 labeled antibodies, 6 negative controls containing bovine serum albumin (BSA), and
empty spots containing no antibody, with the 6 replicates scattered throughout the array.
Cells were lysed and protein extracted using the Protein Extraction Kit (Full Moon
Biosystems). For protein extraction, one tube of Lysis Beads was added to the cell pellet
followed by 200 µl of extraction buffer. This mixture was vortexed for 30 seconds and
incubated on ice for 10 minutes. The mixture was incubated another 60 minutes on ice
and vortexed for 30 seconds every 10 minutes. Following extraction, protein lysate was
purified and the lysis buffer was replaced with the labeling buffer. Spin columns,
containing a dry gel, were reconstituted by adding 650 µl of Labeling buffer, vortexed for
5 seconds, allowed to rest for 30 minutes at room temperature, and vortexed in wash
tubes at 7,500 x g for 2 minutes to remove excess fluid. In a spin column, 100 µl of
protein extract was added directly to the center of the gel bed. The spin column was

	
  

	
  

	
  

	
  

33	
  	
  

placed in a collection tube and centrifuged at 7,500 x g for 2 minutes. Protein lysate was
quantified and checked for quality control by UV absorbance, with absorbance greater
than 4 OD with two separate peaks at 200-230 nm and 240-280 nm. Proteins were
labeled with biotin. For labeling, biotin was dissolved in N,N-dimethylformamide to give a
concentration of 10 µg/ul, mixed with 80 OD of protein lysate, and incubated at room
temperature for 1 hour on a rocking platform at setting 2 (VWR International, Radnor,
PA). Following incubation, stop reagent was added and samples were incubated for 30
minutes at room temperature on a rocking platform.
For the antibody array, slides were first blocked with blocking solution for 30
minutes at room temperature on orbital shaker and washed 10 times for 10 seconds
each with mili-Q water. Biotin-labeled proteins were mixed with coupling solution, poured
onto the slide, incubated on an orbital shaker for 1 hour at room temperature, washed 3
times with 1x wash solution, and washed 10 times for 10 seconds each wash, with mili-Q
water. Slides were incubated with 0.5 mg/ml of Cy3-Streptavidin, incubated on an orbital
shaker for 20 minutes at room temperature in the dark, washed 3 times for 10 minutes
each with 1x wash solution, washed 10 times for 10 seconds each wash with mili-Q
water, and dried by centrifugation. Slides were scanned using Full Moon Biosystems
Scanning Array Service. The protein array procedure is summarized in Figure 2-1.
2.2.6 Array data analysis
Each spot throughout the array was scanned to provide its signal intensity value,
including positive (spots containing Cy-3 labeled antibodies) and negative (empty spots
and spots containing BSA) controls. For background correction, the median value of the
negative control signal was subtracted from the values of each antibody and phosphoantibody. The background corrected signal was log2 transformed and normalized to the
mean value of beta-actin signal. For each phosphorylated antibody, the background-

	
  

	
  

	
  

	
  

34	
  	
  

corrected signal was normalized to the mean value of the corresponding total antibody.
The fold changes between treatment groups were derived from ratios of geometric mean
signal intensities. Treatment groups included: control non-infected monocytes cocultured with HBMEC (control), HIV-1 infected monocytes co-cultured with HBMEC (HIV1), and HIV-1 infected monocytes treated with CCR5 blockers and co-cultured with
HBMEC (HIV-1  +  TAK). ANOVA with heterogeneous variance was used for statistical
analyses of protein expression between groups, and the Tukey-Kramer method used for
multiple comparisons. The Benjamini-Hochberg (BH) method was then used to control
the false discovery rate. Proteins with BH adjusted p-value less than 0.05 were
considered to be differentially expressed.
2.2.7 Ingenuity pathway analysis (IPA)
Differentially expressed and phosphorylated proteins identified in HIV-1-infected
monocytes co-cultured with HBMEC compared to non-infected monocytes co-cultured
with HBMEC or infected monocytes treated with CCR5 blockers and co-cultured with
HBMEC, were analyzed using the Ingenuity Pathways Analysis 3.0 (Ingenuity Systems,
Redwood City, CA). The networks obtained through IPA software describe functional
relationships between protein products based on known interactions, biological
functions, and canonical pathways. Using a false discovery rate of 0.05, only phosphoproteins upregulated or downregulated by at least 1.5-fold were considered; and for nonphosphorylated proteins, only those upregulated or downregulated by at least 2-fold
were considered.
2.2.8 Monocyte adhesion to an in vitro BBB model
HBMEC were plated on 96-well collagen-coated black plates with clear bottoms and
cultured to confluence. Infected monocytes (2.5  ×  105 cells) treated or non-treated with
CCR5 blockers or CCR5 antibodies were labeled with 5-carboxyfluorescein diacetate,
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acetoxymethyl ester (CFDA), 10 µM/1  ×  106 cells for 1 hour, and co-cultured with
HBMEC for 15 min. HBMEC were then washed 3 times with PBS, and the number of
adherent monocytes were quantified by spectrophotometry (excitation: 492 nm,
emission: 517 nm), with a standard curve derived from a serial dilution of a known
number of CFDA-labeled monocytes.
2.2.9 RNA isolation from human brain tissues
Brain tissues (cortex) from nine HIV-1-seropositive patients without neurocognitive
impairment, ten HIV-1-seropositive patients with neurocognitive impairment, and twelve
HIV-seronegative controls were obtained from the National NeuroAIDS Tissue
Consortium and our Department of Pharmacology and Experimental Neuroscience brain
bank. The clinical and demographic histories of all brain tissue donors are detailed in
Table 2-1. Total RNA was extracted from human brain tissues using Trizol reagent (Life
Technologies). One-milliliter of Trizol reagent was added to 50 mg of brain tissue and
tissues were homogenized using the TissueRuptor homogenizer (Qiagen, Valencia, CA).
Homogenized samples were incubated at room temperature for 5 minutes and after
incubation, 200 µl of chloroform was added to each sample, shaken by hand for 15
seconds, and incubated at room temperature for 15 minutes. Samples were centrifuged
at 12,000 x g for 15 minutes at 4 ̊C. During centrifugation the mixture separates into
three layers: a bottom red phenol-chloroform phase, an interphase, and a colorless top
aqueous phase. The aqueous phase was transferred to a new tube and mixed with 500
µl of 100% isopropanol to precipitate RNA. Samples were incubated at room
temperature for 10 minutes followed by centrifugation at 12,000 x g for 10 minutes at
4 ̊C. Supernatant was removed from the tubes and 1 ml of 75% ethanol was added to
each sample, vortexed, and centrifuged at 7,500 x g for 5 minutes at 4 ̊C. Supernatant
was removed and samples were air dried for 5 minutes at room temperature. Pellets
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were re-dissolved in 30 µl of RNase-free water and incubated on a heat block set at
55 ̊C for 10 minutes. RNA was further cleaned using Total RNA cleanup kit (Qiagen).
RNA yield and quality were checked using a NanoDrop spectrophotometer (NanoDrop
Technologies, Wilmington, DE) and for all samples absorbance ratio of 260/280 was ≥ 2.
2.2.10 Reverse transcription and quantitative real-time PCR (qRT-PCR)
For each sample, cDNA was generated from 2 µg RNA using the High Capacity cDNA
Reverse Transcription Kit (Life Technologies). For each sample, 2 µg of RNA in 10 µl of
RNase-free water was mixed with 2 µl 10X RT buffer, 0.8 µl 25X deoxynucleotides
(dNTPs), 2 µl 10X reverse transcription random primers, 1 µl MultiScribeTM reverse
transcriptase, 1 µl RNase inhibitor, and 3.2 µl nuclease-free water. Cycling conditions
were: 10 minutes at 25 ̊C, 120 minutes at 37 ̊C, 5 minutes at 85 ̊C, and hold at 4 ̊C.
A TaqMan gene detection system was used and quantification performed using
the Applied Biosystems StepOnePlus™ system (Life Technologies). For each sample,
the cDNA obtained was diluted in nuclease free water at a ratio of 1:20; a 20 µl reaction
mixture containing 9 µl of each diluted cDNA sample, 10 µl of 2X TaqMan Fast Universal
PCR Master Mix (containing the polymerase enzyme, dNTPs and MgCl2), and 1 µl of
primer-probe [containing 900 nM of each forward and reverse primer and 250 nM
TaqMan minor groove binder (MGB) probe]. Twenty-microliters of reaction mixture
wasloaded into the wells of an optical 96-well fast plate (Life Technologies). The plate
was loaded into the StepOnePlus system and cycling conditions were: 20 second hold at
95 ̊C followed by 40 cycles of 1 second at 95 ̊C and 20 seconds at 60 ̊C. All reagents
and primer-probes (900 nM of each primer and 250 nM TaqMan MGB probe) were
obtained from Applied Biosystems and for endogenous controls, each gene expression
was normalized to GAPDH. Primer IDs were Rac1: Hs01902432_s1, cortactin:
Hs01124225_m1, and GAPDH Hs99999905_m1.
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Data was analyzed using the delta-delta Ct method. The threshold cycle (Ct) of
each sample’s GAPDH target gene was subtracted from the Ct of each sample to give
delta Ct. The delta Ct of HIV-1 samples were subtracted from the delta Ct of the control
sample to give delta-delta Ct. Fold change was calculated by the equation: 2^-delta-delta
Ct.
2.2.11 Protein extraction and western blot analyses
Cells were lysed in a mammalian total protein extraction reagent (Thermo Fisher)
containing 1x Protease Inhibitor Cocktail (Sigma) and 1x phosphatase inhibitor cocktail.
Lysates were kept on ice for 20 mins and centrifuged for 30 mins 13,000 RPM to remove
insoluble materials. Total protein concentration in the resulting supernatant was
measured using the bicinchoninic acid assay (Thermo Fisher). Proteins (40 µg) were
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (80 volts for 1.5
hours) and transferred to nitrocellulose membrane (65 volts for 4 hours). Membranes
were blocked with SuperBlockTM blocking buffer (Thermo Fisher) for 1 hour at room
temperature on a rocking platform followed by incubation with primary antibodies
overnight at 4 ̊C on a rocking platform. Membranes were washed 5 times for 5 minutes
each with 1x western blot wash buffer containing 40 g Dulbecco's phosphate buffered
saline (DPBS, Corning) and 0.001% Tween20 (Sigma), and then incubated with either
anti-mouse or anti-rabbit HRP conjugated antibodies for 1 hour at room temperature on
a rocking platform. Membranes were washed 5 times for 5 minutes each with 1x western
blot wash buffer, incubated with Immobilon Western Chemiluminescent HRP Substrate
(Millipore, Temecula, CA), and developed on x-ray film. ERK1/2 antibodies were from
Cell Signaling (Danvers, MA), while all other antibodies were from Full Moon
Biosystems. All antibodies were used at a 1:1000 dilution. Following Western blot with
phosphorylated antibodies, membranes were stripped using Restore Western Blot
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Stripping Buffer (Thermo Fisher) and re-blotted with the corresponding total antibody,
then stripped again and re-blotted with β-actin antibody to confirm equal loading. Results
were expressed as ratios of relative intensity of the phospho-protein to total protein, or βactin.
2.2.12 Immunofluorescence and confocal microscopy
Sections of human brain tissue were embedded in optimal cutting temperature (OCT)
compound (Sakura Finetek, Torrance, CA). Five-micrometer sections were cut from
each human brain tissue using a Leica CM1860 cryostat (Buffalo Grove, IL) and
mounted on glass slides. Tissue sections were fixed in 4% paraformaldehyde for 20
minutes at room temperature, dried, washed with 1X PBS for 5 minutes at room
temperature, and incubated 1 hour in PBS containing 3% BSA to block for non-specific
binding. Tissue sections were incubated at 4 ̊C overnight with antibodies to phosphoRac1(S71) (1:100), CD163 (1:00), ionized calcium binding adapter molecule-1 (IBA1,
1:50), GFAP (1;100), microtubule-associated protein-2 (MAP2, 1:300), or glucose
transporter-1 (GLUT1,1:100) diluted in PBS containing 3% BSA and 0.1% Triton X-100.
All antibodies were purchased from Abcam (Cambridge, MA). After incubation with
primary antibodies, tissues were washed with 1X PBS 3 times for 5 minutes and stained
with secondary antibodies coupled with Alexa Fluor-488, or −635 (Life Technologies) at
1:500 dilutions for 1 hour in the dark at room temperature. Stained tissues were washed
5 times with 1X PBS and mounted in Prolong Gold anti-fade reagent containing DAPI
(Molecular Probes, Grand Island, NY). For confocal microscopy, stained tissues were
examined under an Olympus FV500-IX 81 confocal laser scanning imaging system. The
triple laser lines excitation were 405 nm for nucleus-stains; 488 nm for CD163, GFAP,
MAP2, IBA1, or GLUT1, and 635 nm for pRac1(S71). A 4th laser line (excitation: 543
nm. Emission: 595-nm) was used to detect auto-fluorescent pigments.
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2.2.13 Statistical analyses
Data were analyzed by t-test (two-tailed) for two-group comparisons and one-way
ANOVA followed by Tukey’s multiple-comparisons tests using GraphPad Prism 5.0b.
(GraphPad Software, La Jolla, CA). Threshold of significance level was 0.05.

2.3 Results
2.3.1 CCR5 blockers prevent HIV-1 infection of macrophages
MVR and TAK are both small molecule CCR5 antagonists that are able to inhibit HIV-1
infection in vitro in a variety of cell types and in vivo [114, 133, 226-229]. To confirm the
effects of CCR5 blockers in human MDM, we infected these cells with HIV-1 in the
presence of TAK or MVR and viral replication was assessed by quantifying viral reverse
transcriptase activity. From day-5 to day-18 post-infection (p.i), MVR diminished MDM
infection by 7.2- to 44-fold (Figure 2-3), while TAK diminished MDM infection by 4.8- to
15.3-fold (Figure 2-4). All data was statistically significant, with p<  0.001.
2.3.2 CCR5 blockers do not affect brain endothelial cell integrity
Several antiretrovirals, including AZT and indinavir have been associated with BBB
dysfunction, which could exacerbate HIV-induced BBB injury [230]. To determine
whether CCR5 blockers could alter endothelial cell integrity, we assessed their effects
on the brain TEER. Exposure of HBMEC to concentrations of 5 µM to 20 µM TAK
(Figure 2-5A) or MVR (Figure 2-5B) did not alter TEER at any time through 48 hours.
Saponin (0.1%) was used as a non-resistant control and was associated with the loss of
endothelial integrity.

	
  

	
  

	
  

	
  

40	
  	
  

2.3.3 CCR5 blockers decrease HIV-1-induced monocyte adhesion
HIV-1 infection has been shown to increase monocyte adhesion to brain endothelial cells
[215]. To determine if CCR5 antagonists could diminish this, we quantified the adhesion
of infected and non-infected monocytes to the BBB, in the presence or absence of CCR5
antagonists, using an in vitro BBB model. HIV-1 infection increased monocyte adhesion
to HBMEC and TAK (5 µM), MVR (5 µM), and CCR5 neutralizing antibodies (25 µg/ml)
significantly decreased HIV-1-induced monocyte adhesion (Figure 2-6).
2.3.4 Increased expression of cytoskeletal proteins in HIV-infected monocytes
following monocyte-endothelial interactions
During migration a monocyte’s cytoskeleton undergoes major reorganization to facilitate
its movement across the endothelium [231]. To determine the changes in cytoskeletonassociated proteins in infected and non-infected monocytes during monocyte-endothelial
interactions, we co-cultured infected or non-infected monocytes with HBMEC in the
presence or absence of the CCR5 antagonist, TAK (5 µM). Co-culture of HIV-1 infected
monocytes with HBMEC induced the upregulation of cytoskeleton-associated proteins in
monocytes compared to uninfected monocytes co-cultured with HBMEC. Of the 141
proteins in the array, 13 proteins were upregulated by 2-fold or more (Table 2-2). The
remaining 128 cytoskeleton-associated proteins were not significantly changed or did not
meet the 2-fold change cut-off. Treatment of monocytes with TAK prevented HIV-1induced upregulation of cytoskeleton-associated proteins during monocyte-endothelial
interactions (Table 2-2).
2.3.5 Altered phosphorylation of cytoskeleton-associated proteins in HIV-1
infected monocytes during monocyte-endothelial interactions
Phosphorylation is known to play a major role in the regulation of protein function,
protein-protein interactions, and cellular functions [232]. Because minor changes in
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protein phosphorylation levels can have functional significance, we used a 1.5-fold
change cut-off to analyze proteins differentially phosphorylated in HIV-1 infected
monocytes following monocyte-endothelial co-culture compared to infected monocytes
treated with TAK and non-infected monocytes co-cultured with HBMEC. Normalization of
each phospho-protein to the expression of its corresponding total protein showed an
increase in the phosphorylation of 9 proteins and a decrease in the phosphorylation of
12 proteins. Thirty-three proteins had no significant change in phosphorylation level.
When proteins were normalized to the sample’s actin levels, 33 proteins showed an
increase in phosphorylation, 7 proteins showed a decrease in phosphorylation, and 25
proteins had no significant change in phosphorylation levels. We then determined the
cytoskeleton-associated proteins that were differentially expressed when normalized to
both their corresponding total proteins and the sample actin levels. Eight proteins
showed significantly increased phosphorylation and 3 proteins showed significantly
decreased phosphorylation when using both normalization methods (Table 2-3). HIV-1
infection and endothelial-monocyte interactions increased the phosphorylation of Merlin
(Ser518), vasodilator-stimulated phosphoprotein (VASP) (Ser157), Rac1 (S71), cortactin
(Tyr421), and ERK1/2 (Tyr204/202) by 4.5 to 6.3-fold, 4-fold, 2.3- to 3.6-fold, 2 to 3-fold,
and 2.4 to 2.6-fold, respectively (Table 2-3). TAK prevented HIV-1-induced
phosphorylation of these cytoskeleton-associated proteins during monocyte-endothelial
interactions (Table 2-3, 2-4). IPA of differentially expressed and phosphorylated proteins
showed that the major biological functions associated with these cytoskeletonassociated proteins and phosphorylation network included cellular assembly and
organization, cellular movement, cell morphology, post-translational modification, cell
cycle, and cell-to-cell signaling (Table 2-5). Canonical pathways activated in HIV-1
infected monocytes co-cultured with HBMEC included chemokine and integrin signaling
and cell junction signaling (Table 2-6).
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2.3.6 Validation of HIV-1-induced activation of Rac1 and ERK1/2 following
monocytes-endothelial interactions, and CCR5 modulation
Rac1 is a cytoskeletal protein that regulates cell polarity and the formation of
lamellipodia, and thus plays an important role in leukocyte transendothelial migration
[233]. ERK1/2 also regulates cellular proliferation, differentiation, and transcriptional
regulation [234]; and both Rac1 and ERK1/2 have been previously implicated in HIV-1
infection [235-238]. Therefore, we performed additional Western blot experiments to
confirm whether HIV-1 infection and monocyte-endothelial interactions induced Rac1
and ERK1/2 activation and to confirm the role of CCR5. The data confirmed our protein
microarray results and showed that HIV-1 infection increased phosphorylation of Rac1 at
S71 and phosphorylation of ERK1/2 in human monocytes following monocyteendothelial communication, and the CCR5 antagonists MVR and TAK diminished HIV-1induced phosphorylation of Rac1 and ERK1/2 (Figure 2-7).
2.3.7 Increased transcription of cortactin (CTTN) and Rac1 in brain tissues of HIV1-infected patients
To determine whether our in vitro findings correlated with changes in HIV-1-infected
humans and to determine if our translational results could be correlated with
transcription, we analyzed the brain tissues of 12 HIV-1 seronegative control subjects, 9
HIV-1-seropositive patients without evidence of HIVE, and 10 HIV-1-seropositive
patients with HIVE and HAND (Table 2.1). All brain tissues were from the cortex region,
with 28 of the 31 samples from the frontal cortex, 2 samples from the parietal cortex, and
1 sample from the temporal cortex. The average age for all individuals was 45.5 years ±
11.15 (range: 27-72 years). The average age was 52 years, 41.78 years, and 41.4 years
for HIV-seronegative, HIV-seropositive, and HIV-seropositve with neurocognitive
impairment, respectively. The average post-mortem interval for all individuals was 7.4
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hours ± 4.31 (range: 2.75-21 hours). The average post-mortem interval was 4.62 hours,
8.53 hours, and 9.72 hours for HIV-seronegative, HIV-seropositive, and HIV-seropositve
with neurocognitive impairment, respectively. RAC1 transcription was upregulated by 3fold and 4-fold in the brain tissues from HIV-1-infected patients compared to brain
tissues from seronegative controls (p<0.01) and HIVE patients (p<0.01), respectively
(Figure 2-8A, B). In addition to RAC1, we examined CTTN transcription. Cortactin
promotes the formation of lamellopodia and subsequent cellular migration [239]; Rac1
can activate cortactin, resulting in the formation of lamellipodia [240]. CTTN transcription
was upregulated by 2.4-fold (p  <  0.001) and 1.6-fold (p  <  0.01) in the brain tissues from
HIV-1-infected patients compared to brain tissues from seronegative controls and HIVE
patients, respectively (Figure 2-8C, D).
2.3.8 Rac1 phosphorylation at S71 is increased in the brain tissues of HIV-1infected patients
Using the brain tissues described in section 2.2.7, we analyzed Rac1 phosphorylation in
human brain tissues. In the first experiment, 4 brain tissue samples were used for each
group: seronegative controls (HIV neg), HIV-1-infected individuals without evidence of
neurocognitive impairment (HIV pos), and HIV-1-infected individuals with HIVE. In HIV1-infected patients there was significant upregulation of phosphorylated Rac1(S71) in
brain tissues compared to brain tissues from seronegative controls (p<0.01) and HIVE
patients (p<0.001; Figure 2-9A,B). An additional western blot experiment with 6 brain
tissue samples from HIV-1-negative and HIV-1-positive individuals further confirmed that
phosphorylated Rac1(S71) is increased in HIV-1-positive individuals (p<0.05; Figures 29C,D).
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2.3.9 Phospho-Rac1 (S71) is expressed in brain macrophages and blood vessel
tight junctions
To determine which cell types in the human brain expresses phospho-Rac1 (S71), we
analyzed brain tissue sections from seronegative controls and HIV-1-infected patients
with and without HIVE by confocal microscopy. Tissues showed high expression of
pRac1 (S71) in brain macrophages (Figure 2-10A-C, white arrows) and blood vessels,
with pRac1(S71) mostly expressed on vessels tight junction strands (Figure 2-10A, C, G,
J-M, orange arrows). Most samples did not show pRac1 expression in microglia (Figure
2-10D, E); however, some HIVE patients did show pRac1 expression in microglia
(Figure 2-10F, white arrows). There was no observed pRac1(S71) expression in
astrocytes (Figure 2-10G-I) or neurons (Figure 2-10J, K) in any of the samples analyzed.
Because lipofuscin-like pigments can accumulate in the human brain and autofluoresce
over a broad excitation and emission spectra [241], we used a 4th laser line (excitation:
543-nm, emission: 595-nm) to differentiate autofluorescent pigments from antibody
staining. These autofluorescent pigments are shown in white (Figure 2-10, yellow
arrows).
2.4 Discussion
In this study, we showed, using a cytoskeleton-associated protein array and western blot
analysis, that HIV-1 infection of monocytes increases the expression of cytoskeletonassociated proteins during interactions with HBMEC and treatment with CCR5
antagonists attenuated these effects. HIV-1 induced phosphorylation of cytoskeletonassociated proteins, including Rac1 at S71 in monocytes during interactions with
HBMEC. This appears to be mediated by CCR5, since CCR5 antagonists attenuated
HIV-1-induced Rac1 S71 phosphorylation. We further showed that HIV-1 infection in
humans is associated with increased transcription of RAC1 and CTTN in brain tissues.
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Rac1 phosphorylation at S71 is increased in the brain tissues of HIV-1 infected
individuals compared to non-infected individuals and those with HAND. We showed by
immunofluorescence analysis of brain tissues that Rac1 phosphorylation at S71
occurred mostly in brain macrophages and blood vessels. Furthermore, CCR5 blockers
reduced the HIV-1-induced increase in monocyte adhesion to the BBB and prevented
viral infection.
Rac1, a member of the Rac subfamily of Rho GTPases, is a small signaling G
protein and a modulator of the cytoskeleton functions; it is involved in cytoskeletal
reorganization, cell-cell adhesion, and motility [242]. Rac1 is ubiquitously expressed and
is the predominant Rac family member found in monocytes, accounting for 90% of Rac
expression [243]. Like most Rho GTPases, Rac1 behaves as a molecular switch
fluctuating between inactive and active states [233]. In its active state, guanosine
triphosphate (GTP) binds Rac1 and in its inactive state it is bound by guanosine
diphosphate (GDP) [233]. Two proteins are involved in regulating the switch between
Rac1 activation and inactivation: Guanine nucleotide Exchange Factors activate Rac1 by
promoting the change of GDP to GTP and GTPase-Activating Proteins inactivate Rac1
by hydrolysis of the bound GTP back into GDP [233]. Rac1 can be activated by a variety
of extracellular stimuli, including GPCRs and integrins [244, 245]. Once activated, Rac1
can activate a variety of molecules, such as ERK1/2, PKB, and STAT [246]. Activation of
these pathways via Rac1 is associated with cell growth and chemotaxis.
Rac1 plays a major role in cell adhesion and migration [233]. In lymphocytes,
activated Rac1 promotes adhesion by cell spreading and this was accompanied by actin
polymerization, cytoskeletal rearrangements, and clustering of integrins [247]. Rac1 can
promote the formation of membrane ruffles and lamellipodia and subsequent migration
in multiple ways. Activation of Rac1 stimulates the actin related protein 2/3 (ARP2/3)
complex through activation of WASP-family verprolin-homologous protein via its
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effectors non-catalytic region of tyrosine kinase adaptor protein-1 (NCK1) associated
protein-1 and cytoplasmic fragile X mental retardation 1 interacting protein-2 (FMR1) or
brain-specific angiogenesis inhibitor 1 associated protein-2 (BAIAP2) [233]. Through its
effector,	
  p21-activated kinase (PAK), Rac1 can induce activation of the actin binding
protein, filamin, a protein important in cross-linking actin filaments [233]. In addition, PAK
can activate LIM (Lin11, Isl-1 & Mec-3 domain) kinase, which in turn inactivates cofilin.
Inactivated cofilin stabilizes actin filaments and filament arrays [233]. The result of these
pathways is the polymerization of new actin filaments and the formation of a branched
network of actin characteristic of lamellipodia and membrane ruffles [233]. Furthermore,
Rac1 S71 phosphorylation has been shown to increase filopodial structures and
enhance cell motility and migration [248]. This suggests that activation of Rac1 in HIV-1infected monocytes following monocyte-endothelial interactions could result in increased
migration of infected monocytes across the blood-brain barrier leading to HIV-1 CNS
infection.
In addition to its role in cell adhesion and migration, there is some evidence that
Rac1 may be involved in inflammatory responses. In macrophages, prostaglandins can
activate the inflammatory molecule cyclooxygenase-2 via Rac1 [249]. Rac1 activity can
promote the activation of NADPH oxidase and the production of reactive oxygen
species, which both can act as proinflammatory mediators [250]. Thus, in addition to its
role in HIV-1-induced monocyte migration, Rac1 may also be involved in oxidative stress
and the inflammatory response during HIV-1 infection.
Previous studies have also suggested a role for Rac1 in HIV-1 infection. Nef
activates PAK1 through association with Rac1, and a dominant-negative form of Rac1
decreased viral production levels [237, 251]. Nef activation of PAK1 via Rac1 resulted in
cytoskeletal rearrangements, such as increased lamellipodia [252, 253]. In addition,
Rac1 appears to be necessary for CD28-dependent HIV-1 transcription in T-cells and
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internalization of the Tat protein transduction domain, a small region of Tat that is
responsible for translocating Tat across the cellular membrane [236, 254]. Lastly,
activated Rac1 is involved in Gag plasma membrane localization and viral particle
production [255].
CCR5 can interact with Rac1 and these interactions are involved in HIV-1
infection and migration. Binding of viral Env to the CD4 receptor and CCR5 or CXCR4
co-receptors induces a signaling cascade through Gαq that results in Rac1 activation,
actin cytoskeletal reorganizations, and membrane fusion, which are necessary for
efficient viral infection [27, 256, 257]. HIV-1 infection of macrophages via endocytosis
requires Rac1 [235]. In addition, activation of CCR5 in macrophages results in Rac1
activation, cytoskeletal reorganization, and formation of lamellipodia; and a Rac
dominant–negative mutation blocked these effects [221].
Cortactin, which was identified in our protein array and further shown to be
transcriptionally upregulated in the brains of HIV-1-infected individuals, is a cytoskeletal
protein that is localized to the sites of actin assembly and play a crucial role in the
formation of lamellipodia [258]. Rac1 activates cortactin, allowing cortactin to bind and
activate the ARP2/3 complex, leading to the formation of lamellipodia [240].
Overexpression of cortactin is associated increased invasiveness of several types of
cancers, including head and neck squamous cell carcinoma, breast cancer, colorectal
cancer, and melanoma [239]. Cortactin overexpression in cancer is thought to alter
cellular migration [239]. Although not previously implicated in HIV-1-infection, increased
expression of cortactin in infected cells could lead to increased migration of these cells.
HIV-1 induced transcriptional regulation of Rac1 and cortactin likely occurs
during the earlier stages of infection, as our data showed increased Rac1 and cortactin
transcription in the brain tissues of HIV-1 infected individuals without evidence of
neurocognitive impairment compared to seronegative controls or HIV-1 infected
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individuals with HAND/HIVE. This likely correlates with BBB breach and increased
trafficking of monocytes into the CNS, which is known to precede HAND/HIVE [259].
Previous studies by our laboratory have shown increased transcriptional upregulation of
proinflammatory cytokines in brain tissues of HIV-1+/nonencephalitic patients compared
to brain tissues of seronegative controls and HAND/HIVE patients, further confirming
that increased inflammation and inflammation-induced damages that leads to HIVE and
HAND often precede the onset of HIVE/HAND [215]. Rac1 activation is associated with
clustering of cell adhesion molecules, leukocyte migration, and increased production of
reactive oxygen species [233]. These events are all associated with HIV-1 CNS
dysfunction and occur prior to the onset of HAND/HIVE [260]. In accordance with these
studies, we suggest that gp120 binding to CCR5 in monocytes and the interactions of
these infected monocytes with the brain endothelium results in activation of Rac1 and
cortactin, which in turn increases monocyte adhesion and migration through the BBB,
resulting in increased infiltration of infected monocytes into the CNS. Furthermore,
activation of Rac1 could result in increased expression of proinflammatory molecules,
causing further damage to the BBB and CNS.
2.5 Summary
HIV-1 infection of monocytes is associated with increased adhesion to the brain
endothelium. This adhesion, as well as viral replication in macrophages, can be blocked
by the use of CCR5 antagonists. On their own, CCR5 blockers are not toxic to
monocytes/macrophages and do not affect BBB integrity. Using a cytoskeletonassociated protein array we found that HIV-1 infection of monocytes increased the
expression and phosphorylation of cytoskeleton-associated proteins, including
phosphorylation of Rac1 at S71 and cortactin, during interactions with brain endothelial
cells. These proteins are involved in cellular assembly, cellular movement, and cell
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morphology; and blocking HIV-1 infection in monocytes by the use of CCR5 antagonists
prevented these changes. Rac1 mRNA expression and phosphorylation at S71 was
increased in human brain tissues from HIV-1-infected individuals, compared to
seronegative controls and HIV-1-infected individuals with HAND/HIVE. Lastly, we found
that phosphorylated Rac1 S71 was expressed mainly in brain macrophages and blood
vessel tight junctions. We suggest that HIV-1 binding to CCR5 in monocytes and the
interactions of these infected monocytes with the brain endothelium results in activation
cytoskeletal-associated proteins, which in turn increases monocyte adhesion and
migration through the BBB, resulting in increased infiltration of infected monocytes into
the CNS.
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2.6 Figures and tables

	
  

	
  

Figure 2-1: Summary of co-culture experiments. Freshly elutriated monocytes were
treated with 5 µM TAK or MVR for 30 minutes followed by infection with HIV-1ADA for 12
hours and were washed three times with PBS to remove free virions. Monocytes were
then resuspended in fresh media and co-cultured with HBMEC for 2 hours in a 5:1 ratio.
Treatment conditions were: Untreated, uninfected monocytes; treated (5 µM TAK or
MVR), uninfected monocytes; untreated, infected monocytes; and treated (5 µM TAK or
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MVR), infected monocytes. Cells were harvested separately and protein was extracted
and quantified as described in Methods (2.2.5 and 2.2.11). Monocyte protein lysates
were used for cytoskeleton-associated protein array and western blot experiments as
described in Methods (2.2.5 and 2.2.11), and HBMEC protein lysates were frozen for
future experiments.
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Figure 2-2: General outline of the antibody array. Monocytes were lysed and protein
extracted following co-culture with HBMEC using the Full Moon protein extraction kit.
Samples were biotinylated for 1 hour. Array slides were blocked for 30 minutes followed
by washing and labeled proteins were incubated with array slides for 1 hour followed by
washing. Slides were incubated with Cy3-streptavidin for 20 minutes, washed with

	
  

	
  

	
  

	
  

washing buffer, and then washed with water. Slides were scanned using Full Moon
Biosystems Scanning Array Service.
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HIV-1
Status

	
  

ID

Gender/
Age (y)

PMI (h)

54	
  	
  

Neurocognition/
Neuropathology

Neg
Neg
Neg

N1
N2
N3

M/35
N/A
F/38

8.5
N/A
5.75

Neg

N4

M/32

4.25

Neg

N5

F/46

4

Neg

N6

F/49

4.5

Neg

N7

M/52

5.25

Neg
Neg
Neg

N8
N9
N10

M/72
M/64
M/56

3
3.3
3

Normal/None
Normal/None
Normal/Not
significant

Neg
Neg

N11
N12

M/67
M/61

3.5
5.75

Pos
Pos
Pos
Pos

P1
P2
P3
P4

?/46
?/27
?/37
M/39

2.75
8
5
11

Normal/None
Normal/Not
significant
Normal/None
Normal/None
Normal/None
Normal/None

Pos

P5

M/35

6.5

Normal/None

Pos
Pos
Pos
Pos

P6
P7
P8
P9

M/54
M/48
M/52
M/38

6.5
15
8
14

Normal/None
Normal/None
Normal/None
Normal

Pos

HAD1
/D1
HAD2
/D2
HAD3
/D3
HAD4
/D4
HAD5
/D5

M/30

6

HAD/HIVE

Mild Alzheimer gliosis
N/A
Mild gliosis, lung and bile
duct carcinoma
Cystic fibrosis, and
multiorgan failure
Mild fibrosis, mild patchy
gliosis
Hepatic cirrhosis, liver
failure
Hypertension, renal
failure
Hypertension, COPD
Hepatic carcinoma
Lung adenocarcinoma,
mild nonspecific cortical
atrophy
COPD, TB
Cardiomyopathy, mild
gliosis
N/A
N/A
N/A
Minimal non-diagnostic
abnormalities
Non-Hodgkins
lymphoma, AIDS
AIDS
Liver disease
AIDS
Pneumonia, hemophilia
A, AIDS
Minimal terminal anoxia

?/50

21

HAD/HIVE

N/A

?/39

12

HAD/HIVE

N/A

?/40

12

HAD/HIVE

N/A

M/47

11

HAD/HIVE

HAD6

M/40

5

HAD/HIVE

Encephalopathy,
microglial nodule
encephalitis,
meningoencephalitis with
microvascular damage
Non-Hodgkin’s

Pos
Pos
Pos
Pos

Pos

Normal/None
Normal/None
Normal/Not
significant
Normal/Not
significant
Normal/Not
significant
Normal/Not
significant
Normal/None

Other autopsy
diagnosis

	
  

	
  

	
  

	
  
/D6
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Pos

HAD7
/D7

M/44

4

HAD/HIVE

Pos

HAD8
/D8
HAD9
/D9
HAD1
0/D10

M/52

5

HAD/HIVE

lymphoma, AIDS,
lymphocytic meningitis
Microglial nodules,
astrocytosis, widespread
gliosis, AIDS
Atherosclerosis

M/34

11.5

HAD/HIVE

AIDS

M/38

7

HAD/HIVE

HIV encephalopathy /
Leukoencephalopathy,
AIDS

Pos
Pos

Table 2-1: Clinical history of brain tissues donors. Neg indicates HIV seronegative;
Pos, HIV seropositive; HAD, HIV-associated dementia; HIVE, HIV encephalitis; y, years;
M, male; F, female; ? or N/A, not available; and PMI, postmortem interval; AIDS,
acquired immunodeficiency syndrome; COPD: chronic obstructive pulmonary disease;
TB, tuberculosis. Modified from Woollard, S.M., Li, H., Singh S., Yu F., and Kanmogne
G.D. (2014) HIV-1 induces cytoskeletal alterations and Rac1 activation during monocyteblood-brain barrier interactions: modulatory role of CCR5. Retrovirology. 11:20 [261].
Reprinted with permission under the Creative Commons Attribution License or
equivalent.
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Figure 2-3: The CCR5 antagonist, MVR, inhibits HIV-1 infection in MDM. MDM were
infected with the macrophage tropic HIV-1ADA with or without MVR (5 µM) in the media.
Controls consisted of mock-infected cells. Culture supernatants were collected every 2
or 3 days from day-5 to day-18 p.i and viral replication estimated by quantifying the
reverse transcriptase activity. MVR inhibited HIV-1 infection from as early as day-5 and
up to day-18 p.i. This is a representative data from 3 independent experiments using 3
different human donors, with each donor tested in triplicate. One-way ANOVA followed
by Tukey’s multiple-comparisons tests was performed using GraphPad Prism 5.0b to
determine significance. Threshold of significance level was 0.05. ***P  <  0.001. Error bars
represent standard error of mean (SEM). Modified from Woollard, S.M., Li, H., Singh S.,
Yu F., and Kanmogne G.D. (2014) HIV-1 induces cytoskeletal alterations and Rac1
activation during monocyte-blood-brain barrier interactions: modulatory role of CCR5.
Retrovirology. 11:20 [261]. Reprinted with permission under the Creative Commons
Attribution License or equivalent.
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Figure 2-4: The CCR5 antagonist, TAK, inhibits HIV-1 infection in MDM. MDM were
infected with the macrophage tropic HIV-1ADA with or without TAK (5 µM) in the media.
Controls consisted of mock-infected cells. Culture supernatants were collected every 2
or 3 days from day-5 to day-18 p.i. and viral replication estimated by quantifying the
reverse transcriptase activity. TAK inhibited HIV-1 infection from as early as day-5 and
up to day-18 p.i. This is representative data from 3 independent experiments using 3
different human donors, with each donor tested in triplicate. One-way ANOVA followed
by Tukey’s multiple-comparisons tests was performed using GraphPad Prism 5.0b to
determine significance. Threshold of significance level was 0.05. ***P  <  0.001. Error bars
represent SEM. Modified from Woollard, S.M., Li, H., Singh S., Yu F., and Kanmogne
G.D. (2014) HIV-1 induces cytoskeletal alterations and Rac1 activation during monocyteblood-brain barrier interactions: modulatory role of CCR5. Retrovirology. 11:20 [261].
Reprinted with permission under the Creative Commons Attribution License or
equivalent.
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Figure 2-5: Effects of CCR5 antagonists on the BBB integrity. Confluent HBMEC
monolayers were treated with TAK (A) or MVR (B) at concentrations of 5, 10, or 20 µM
and TEER was measured in real-time before and after exposures. Neither TAK-779 nor
MVR altered TEER. TEER values were similar during treatment and when cells were
washed to remove CCR5 antagonists. Controls consisted of mock-treated cells and cells
treated with 0.1% saponin. Saponin-induced decrease in TEER was reversed upon
removal of saponin from the media. Modified from Woollard, S.M., Li, H., Singh S., Yu
F., and Kanmogne G.D. (2014) HIV-1 induces cytoskeletal alterations and Rac1

	
  

	
  

	
  

	
  

activation during monocyte-blood-brain barrier interactions: modulatory role of CCR5.
Retrovirology. 11:20 [261]. Reprinted with permission under the Creative Commons
Attribution License or equivalent.
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Figure 2-6: CCR5 blockers decrease HIV-1-induced monocyte adhesion. HMBEC
were grown to confluency on clear-bottom 96-well black plates. Monocytes (2.5 x
105/condition) were treated with TAK or MVR (5 µM) or CD195, a CCR5 neutralizing
antibody (25 µg/ml) prior to HIV-1 infection, stained with 10 µM CFDA, and co-cultured
with HBMEC for 15 minutes. Monocytes adhesion to HBMEC was quantified by
spectrophotometry (excitation: 492 nm, emission: 517 nm). Controls consisted of
untreated uninfected cells and cells treated with isotyped-matched control IgG (25
µg/ml). HIV-1 increased monocyte adhesion to HBMEC. Treatment with CCR5
antagonists decreased viral-induced monocyte adhesion. One-way ANOVA followed by
Tukey’s multiple-comparisons tests was performed using GraphPad Prism 5.0b to
determine significance. Threshold of significance level was 0.05. *p  <  0.01; ***p  <  0.001.
Error bars represent SEM. Modified from Woollard, S.M., Li, H., Singh S., Yu F., and

	
  

	
  

	
  

	
  

Kanmogne G.D. (2014) HIV-1 induces cytoskeletal alterations and Rac1 activation
during monocyte-blood-brain barrier interactions: modulatory role of CCR5.
Retrovirology. 11:20 [261]. Reprinted with permission under the Creative Commons
Attribution License or equivalent.
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Protein

HIV-1 vs.
control fold
change
p-value

HIV-1 vs.
TAK fold
change

p-value

Location

Src

3.05

5.09E-10

0.67

3.34E-05

Cytoplasm

MKK3/MAP2K3

2.78

3.62E-09

0.41

1.16E-11

Cytoplasm

PKC alpha

2.56

7.34E-08

0.57

6.81E-06

Cytoplasm

p130Cas

2.51

2.06E-08

0.54

1.16E-11

Plasma
membrane

MKK7/MAP2K7

2.41

5.47E-09

0.45

1.16E-11

Cytoplasm

CaMK2beta/gamma/delta 2.40

1.61E-09

0.69

3.61E-04

Nucleus

Ezrin

2.22

4.15E-10

0.50

1.16E-11

Plasma
membrane

PLC beta3

2.17

3.62E-09

0.48

1.09E-06

Cytoplasm

c-Raf

2.07

1.99E-11

0.57

1.29E-11

Cytoplasm

PLC-beta

2.04

7.50E-07

0.53

2.09E-10

Cytoplasm

WAVE1

2.02

3.19E-06

1.17

1.61E-03

Nucleus

LIMK1

1.99

1.99E-11

0.46

3.08E-11

Cytoplasm

Myosin regulatory
light chain 2

1.99

5.47E-09

0.63

7.03E-11

Cytoplasm

Table 2-2: Differentialy expressed total proteins in HIV-1 infected-monocytes cocultured with HBMEC. Table shows p-values adjusted using the Benjamini & Hochberg
method. Src: v-src sarcoma viral oncogene homolog; MKK3/MAP2K3: mitogen-activated
protein kinase kinase3; PKC: protein kinase C; p130Cas: breast cancer anti-estrogen
resistance 1; MKK7/MAP2K7: mitogen-activated protein kinase kinase 7; CAMK2:
calcium/calmodulin-dependent protein kinase-2; PLC: phospholipase C; c-raf: v-raf-1
murine leukemia viral oncogene homolog 1; WAVE1: WAS protein family 1; LIMK1: LIM
domain kinase 1. Modified from Woollard, S.M., Li, H., Singh S., Yu F., and Kanmogne
G.D. (2014) HIV-1 induces cytoskeletal alterations and Rac1 activation during monocyte-

	
  

	
  

	
  

	
  

blood-brain barrier interactions: modulatory role of CCR5. Retrovirology. 11:20 [261].
Reprinted with permission under the Creative Commons Attribution License or
equivalent.
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HIV-1 vs. CONTROL

66	
  	
  
HIV-1  +  TAK vs.
CONTROL

HIV-1 vs. HIV-1  +  TAK

Fold
change

p-value

Fold
change

p-value

Fold
change

p-value

Merlin (PhosphoSer518)

4.47

8.13E-12

1.39

8.97E-05

0.31

1.45E-10

VASP (PhosphoSer157)

4.05

8.13E-12

1.29

0.00047

0.32

1.84E-11

ERK1-p44/42
MAP Kinase
(Phospho-Tyr204)

2.38

4.31E-08

1.14

0.10

0.48

3.68E-09

Rac1/cdc42
(Phospho-Ser71)

2.24

1.28E-05

0.85

0.17

0.38

1.76E-07

Cortactin
(Phospho-Tyr421)

1.20

8.13E-12

0.63

1.53E-10

0.31

1.84E-11

CaMK1-a
(Phospho-Thr177)

1.93

5.75E-05

1.47

0.0092

0.76

0.00013

ERK1-p44/42
MAP Kinase
(Phospho-Thr202)

1.74

6.72E-08

1.15

1.13E-05

0.66

3.71E-06

ERK3 (PhosphoSer189)

1.68

7.74E-05

1.10

0.556

0.65

0.0035

MEK1(PhosphoSer217)

1.47

0.00017

0.83

0.00034

0.57

4.63E-06

MKK6 (PhosphoSer207)

0.49

8.13E-12

0.49

1.53E-10

1.01

0.96

FAK (PhosphoTyr397)

0.44

8.13E-12

0.87

0.0552

1.97

8.0E-09

MKK7/MAP2K7
(Phospho-Ser271)

0.30

8.13E-12

0.81

0.0344

2.65

1.5

Name

Table 2-3: Phosphorylated proteins differentially expressed in HIV-1 infectedmonocytes co-cultured with HBMEC, when normalized to total proteins. Table
shows p-values adjusted using the Benjamini & Hochberg method. VASP: vasodilatorstimulated phosphoprotein; CaMK1: calcium/calmodulin-dependent protein kinase-1;
ERK: extracellular signal-regulated kinases; MEK / MKK: mitogen-activated protein
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kinase kinase; FAK: focal adhesion kinase. Modified from Woollard, S.M., Li, H., Singh
S., Yu F., and Kanmogne G.D. (2014) HIV-1 induces cytoskeletal alterations and Rac1
activation during monocyte-blood-brain barrier interactions: modulatory role of CCR5.
Retrovirology. 11:20 [261]. Reprinted with permission under the Creative Commons
Attribution License or equivalent.

	
  

	
  

	
  

	
  
HIV-1 vs.
CONTROL
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HIV-1  +  TAK vs.
CONTROL

HIV-1 vs. HIV1  +  TAK

Fold
change

p-value

Fold
change

p-value

Fold
change

p-value

Merlin (PhosphoSer518)

6.24

1.95E-11

1.15

0.079

0.184

1.16E-11

VASP (PhosphoSer157)

4.38

1.95E-11

0.88

0.088

0.20

1.16E-11

Rac1/cdc42 (PhosphoSer71)

3.56

3.67E-08

0.83

0.14

0.23

6.98E-10

ERK1-p44/42 MAP
Kinase (PhosphoTyr204)

3.26

9.42E-10

0.88

0.13

0.27

1.16E-11

Cortactin (PhosphoTyr421)

2.93

1.96E-11

0.73 7.19E-08

0.25

1.16E-11

ERK1-p44/42 MAP
Kinase (PhosphoThr202)

2.55

1.2E-10

0.92

0.0028

0.34

3.18E-11

MEK1(PhosphoSer217)

2.23

2.06E-08

0.74 2.35E-06

0.33

7.81E-10

CaMK1-a (PhosphoThr177)

1.67

0.00038

1.08

0.91

0.64

3.19E-07

ERK3 (PhosphoSer189)

1.61

0.00011

1.06

0.91

0.65

0.0026

MKK7/MAP2K7
(Phospho-Ser271)

0.73

1.51E-06

0.87

0.23

1.18

0.038

FAK (Phospho-Tyr397)

0.61

1.96E-11

0.64 2.82E-06

1.05

0.63

MKK6 (PhosphoSer207)

0.60

1.96E-11

0.71 2.27E-06

1.17

0.00089

Name

Table 2-4: Phosphorylated proteins differentially expressed in HIV-1 infectedmonocytes co-cultured with HBMEC, when normalized to actin levels. Table shows
p-values adjusted using the Benjamini & Hochberg method. Modified from Woollard,
S.M., Li, H., Singh S., Yu F., and Kanmogne G.D. (2014) HIV-1 induces cytoskeletal
alterations and Rac1 activation during monocyte-blood-brain barrier interactions:

	
  

	
  

	
  

	
  

modulatory role of CCR5. Retrovirology. 11:20 [261]. Reprinted with permission under
the Creative Commons Attribution License or equivalent.
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Differentially expressed total proteins
Molecular and cellular functions

p-value

N

Cellular Assembly and Organization

9.10E-08 - 9.06E-03

11

Cellular Movement

1.75E-07 - 9.06E-03

11

Cell Morphology

2.35E-07 - 9.76E-03

11

Cellular Function and Maintenance

3.24E-07 - 9.06E-03

11

Cellular Development

3.74E-07 - 9.68E-03

9

Differentially expressed phospho-proteins
Molecular and cellular functions

p-value

N

Cell Cycle

4.42E-11 - 5.12E-03

10

Cell Signaling

6.64E-10 - 5.07E-03

9

Cellular Movement

1.23E-09 - 5.24E-03

8

Cell Morphology

3.71E-09 - 5.12E-03

10

Post-translational Modification

4.87E-09 - 5.07E-03

10

Table 2-5: Molecular and cellular functions associated with differentially
expressed total and phosphorylated proteins in HIV-1 infected monocytes
following monocytes-endothelial interactions. N = number of associated proteins.
Modified from Woollard, S.M., Li, H., Singh S., Yu F., and Kanmogne G.D. (2014) HIV-1
induces cytoskeletal alterations and Rac1 activation during monocyte-blood-brain barrier
interactions: modulatory role of CCR5. Retrovirology. 11:20 [261]. Reprinted with
permission under the Creative Commons Attribution License or equivalent.
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Differentially expressed total proteins
Canonical pathways

p-value

N

Chemokine Signaling

3.08E-12

6

Melatonin Signaling

3.37E-12

6

Role of NFAT in Cardiac Hypertrophy

1.02E-11

7

Cholecystokinin/Gastrin-mediated Signaling

3.23E-11

6

GNRH Signaling

1.52E-10

6

p-value

N

GNRH Signaling

7.51E-11

6

Germ Cell-Sertoli Cell Junction Signaling

2.29E-10

6

Integrin Signaling

9.39E-10

6

HGMB1 Signaling

1.9E-09

5

2.74E-09

5

Differentially expressed phospho-proteins
Canonical pathways

HGF Signaling

Table 2-6: Canonical pathways associated with differentially expressed total and
phosphorylated proteins in HIV-1 infected monocytes following monocyteendothelial interactions. N = number of associated proteins. Modified from Woollard,
S.M., Li, H., Singh S., Yu F., and Kanmogne G.D. (2014) HIV-1 induces cytoskeletal
alterations and Rac1 activation during monocyte-blood-brain barrier interactions:
modulatory role of CCR5. Retrovirology. 11:20 [261]. Reprinted with permission under
the Creative Commons Attribution License or equivalent.
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Figure 2-7: Increased levels of pRac1 (S71) and pERK1/2 (Thr202/Tyr204) in HIV-1
infected monocytes co-cultured with HBMEC. Monocytes were treated with 5 µM
TAK or 5 µM MVR for 30 minutes prior to 12 hours infection with HIV-1. Following
infection, monocytes were washed 3 times with PBS to remove free virus, and cocultured with HBMEC for 2 hours. Protein was purified from monocytes and HBMEC
separately. Monocyte protein was fractionated on an SDS-PAGE gel and transferred to a
nitrocellulose membrane as described in the Methods (2.2.11). HIV-1-infected
monocytes showed increased levels of pRac1 (S71) and pERK1 (Thr202/Tyr204)
following monocyte-endothelial interactions, compared to non-infected monocytes cocultured with HBMEC. TAK and MVR reduced HIV-1-induced phosphorylation of Rac1
and ERK1/2. Modified from Woollard, S.M., Li, H., Singh S., Yu F., and Kanmogne G.D.
(2014) HIV-1 induces cytoskeletal alterations and Rac1 activation during monocyteblood-brain barrier interactions: modulatory role of CCR5. Retrovirology. 11:20 [261].
Reprinted with permission under the Creative Commons Attribution License or
equivalent.
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Figure 2-8: Increased transcription of RAC1 and CTTN in brain tissues of HIV-1infected humans. Total RNA was extracted from the brains (cortex) of HIV-1seronegative individuals or HIV-1-seropositive patients with or without neurocognitive
impairment using Trizol followed by revere transcription as described in methods section
2.2.10. Quantitative real-time PCR was performed using the Taqman detection system
using the Applied Biosystems StepOne Plus system. Data was quantified using the
delta-delta Ct method. Quantitative real-time PCR show overall increase in Rac1 (A, B)
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and cortactin (C, D) mRNA in brain tissues of HIV-1-positive individuals (HIV-1 Pos),
compared to seronegative controls (HIV-1 Neg) and HIV-1-infected patients with
encephalitis (HIVE). One-way ANOVA followed by Tukey’s multiple-comparisons tests
was performed using GraphPad Prism 5.0b to determine significance. Threshold of
significance level was 0.05. Error bars represent SEM. Modified from Woollard, S.M., Li,
H., Singh S., Yu F., and Kanmogne G.D. (2014) HIV-1 induces cytoskeletal alterations
and Rac1 activation during monocyte-blood-brain barrier interactions: modulatory role of
CCR5. Retrovirology. 11:20 [261]. Reprinted with permission under the Creative
Commons Attribution License or equivalent.
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Figure 2-9: Increased phosphorylation of Rac1(S71) in brain tissues of HIV-1infected humans. Protein was extracted from brains (cortex) of HIV-1-seronegative
individuals or HIV-1-seropositive humans with or without neurocognitive impairment.
Protein was fractionated on an SDS-PAGE gel, transferred to a nitrocellulose
membrane, and analyzed as described in methods section 2.2.11. A and B: Western blot
analysis of brain tissue show increased levels of pRac1 (S71) in brain tissues of HIV-1seropositive individuals (HIV Pos; N=4) compared to HIV-1-infected patients with
encephalitis (HIVE; N=4) and seronegative controls (HIV-1 Neg; N=4). C and D:
Confirmation of pRac1 (s71) in the brain tissues of HIV-1-positive individuals (HIV Pos;
N=6) compared to seronegative controls (HIV Neg; N=6). Statistical significance was
determined by One-way ANOVA followed by Tukey’s multiple-comparisons tests (B), or
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a tow-tailed t-test (D), using GraphPad Prism 5.0b. Error bars represent SEM. Modified
from Woollard, S.M., Li, H., Singh S., Yu F., and Kanmogne G.D. (2014) HIV-1 induces
cytoskeletal alterations and Rac1 activation during monocyte-blood-brain barrier
interactions: modulatory role of CCR5. Retrovirology. 11:20 [261]. Reprinted with
permission under the Creative Commons Attribution License or equivalent.
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Figure	
  2-‐10:	
  Expression	
  of	
  pRac1	
  (S71)	
  in	
  human	
  brain	
  macrophages	
  and	
  
blood	
  vessels.	
  Five-‐micrometer	
  sections	
  of	
  brain	
  tissue	
  from	
  HIV-‐1-‐seronegative	
  
individuals	
  or	
  HIV-‐1-‐seropositive	
  humans	
  with	
  or	
  without	
  neurocognitive	
  
impairment,	
  were	
  mounted	
  on	
  glass	
  slides,	
  fixed,	
  permeabilized,	
  and	
  incubated	
  1	
  
hour	
  in	
  PBS	
  containing	
  3%	
  BSA	
  to	
  block	
  for	
  non-‐specific	
  binding.	
  Tissues	
  were	
  
incubated	
  overnight	
  with	
  antibodies	
  to	
  phospho-‐Rac1(S71)	
  and	
  CD163,	
  IBA1,	
  GFAP,	
  
MAP2,	
  or	
  GLUT1,	
  followed	
  by	
  staining	
  (1	
  hour	
  in	
  the	
  dark	
  at	
  room	
  temperature)	
  
with	
  secondary	
  antibodies	
  coupled	
  with	
  Alexa	
  Fluor-‐488	
  or	
  −635,	
  washed	
  and	
  
mounted	
  as	
  described	
  in	
  section	
  2.2.12.	
  Confocal	
  microscopy	
  showed	
  expression	
  of	
  
pRac1(S71)	
  in	
  human	
  brain	
  macrophages	
  (A-‐C,	
  white	
  arrows)	
  and	
  blood	
  vessels	
  
tight	
  junction	
  strands	
  (A,	
  C,	
  G,	
  J-‐M	
  orange	
  arrows).	
  There	
  was	
  no	
  significant	
  
expression	
  of	
  pRac1	
  (S71)	
  in	
  microglia	
  in	
  most	
  brain	
  tissues	
  (D,	
  E);	
  but	
  a	
  few	
  HIVE	
  
patients	
  did	
  show	
  expression	
  of	
  pRac1(S71)	
  in	
  microglia	
  (F,	
  white	
  arrows).	
  There	
  
was	
  no	
  expression	
  of	
  pRac1	
  (S71)	
  in	
  astrocytes	
  (G-‐I)	
  or	
  neurons	
  (J,	
  K).	
  For	
  all	
  
experiments,	
  a	
  4th	
  laser	
  line	
  was	
  used	
  to	
  differentiate	
  lipofuscin-‐like	
  
autofluorescent	
  pigments	
  from	
  antibody	
  staining	
  (yellow	
  arrows).	
  Scale	
  bar	
  for	
  all	
  
panels:	
  20	
  μM.	
  Modified from Woollard, S.M., Li, H., Singh S., Yu F., and Kanmogne
G.D. (2014) HIV-1 induces cytoskeletal alterations and Rac1 activation during monocyteblood-brain barrier interactions: modulatory role of CCR5. Retrovirology. 11:20 [261].
Reprinted with permission under the Creative Commons Attribution License or
equivalent.

	
  

	
  

	
  

	
  

	
  

Chapter 3
Maraviroc reduces HIV-induced BBB injury and HIV CNS
infection in Hu-PBL-NOD/SCID mice
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3.1 Background
HIV-1 often enters the CNS before individuals are aware of infection, as early as 8-14
days post-infection [262, 263]. HIV-1 induces BBB breakdown, which results in viral
entry into the CNS; productive viral infection and inflammation in the CNS further
exacerbate BBB breakdown and increase the entry of HIV-1 virions and infected cells
into the brain [152]. Post-mortem analysis of brain tissue samples from HIV-1-positive
patients with HAD showed reduced expression of the tight junction proteins ZO-1,
occludin, and claudin-5 [264]. Since the introduction of ART, the prevalence of the most
severe stage of HAND, HAD, has decreased [158]. However, the prevalence of the
milder stages, ANI and MND, have increased, and this appears to be related to the
increasing life expectancy of HIV-1-infected patients on ART [158].
The role of MVR in preventing BBB dysfunction and CNS injury has not been
previously investigated. Using an in vitro BBB model we showed that treatment of
monocytes with CCR5 antagonists was associated with a decrease in HIV-1-induced
adhesion to brain endothelial cells [261]. We further showed that CCR5 antagonists
reduced HIV-1-induced expression and activation of cytoskeleton-associated proteins
[261]. Others have found that MVR is detectable in the CSF of HIV-1-infected patients
and is associated with decreased CSF viral loads [121, 123-125]. MVR was also shown
to be neuroprotective in SIV-infected rhesus macaques [265] and is able to inhibit T-cell,
monocyte, macrophage, and dendritic cell migration induced by chemokines in vitro
[224, 225, 266]. However, it has not been determined if MVR can enter the CNS and
reduce HIV-1 viral load in the CNS.
We hypothesized that blocking CCR5, through treatment with MVR, would
prevent HIV-1-induced CNS injury and reduce infection levels in the brain. To test this
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hypothesis, we used a Hu-PBL-NSG mouse model infected with HIV-1 and treated with
a human-equivalent mouse dose of MVR, to analyze the effect of MVR treatment on
engrafted human cells, blood and CNS viremia, and BBB integrity (Figure 4-1). We
further quantified MVR levels in the brain to determine if MVR could enter into the CNS.
3.2 Materials and Methods
3.2.1 MVR preparation for injection
MVR (Selzentry; ViiV Healthcare) in 300 mg tablets was purchased from the Nebraska
Medical Center pharmacy. To prepare stock concentrations of 75 mg/ml, 1 tablet was
crushed using a mortar and pestle and dissolved in 4 ml of a 1:1 mixture of dimethyl
sulfoxide (DMSO) and PBS. Stock solutions were stored at -80°C in 600 µl aliquots and
used within 2 days of preparation. For animal injections, 500 µl of stock solution was
further diluted in 2 ml PBS for a working concentration of 18.75 mg/ml. This solution was
filtered using a 0.45 µM syringe filter to remove undissolvable drug excipients. Each
mouse was injected intraperitoneally (I.P.) with 200 µl of working solution, for a final
amount of 3 mg MVR per mouse. For untreated mice, solutions were prepared in a
similar fashion: a stock solution of a 1:1 mixture of DMSO and PBS was prepared in 4
ml. This solution was frozen at -80°C in 600 µl aliquots. For injections, 500 µl of the
PBS/DMSO solution was further diluted in 2 ml PBS, and each mouse received I.P.
injections of 200 µl.
3.2.2 Hu-PBL-NOD/SCID mouse model
Four-week old male nonobese diabetic (NOD)/ severe combined immune deficiency
(SCID), IL2 receptor gamma chain knockout mice: NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ
(NSG) mice were purchased from Jackson Laboratory (Bar Harbor, ME) and maintained
in sterile microisolator cages under pathogen-free conditions in accordance with ethical
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guidelines for care of laboratory animals at the University of Nebraska Medical Center
and National Institutes of Health. Animals were injected I.P. with human PBL (30 ×106
cells/mouse) at 4 to 6 weeks of age. At 1 to 2 weeks after engraftment, animals’ blood
was analyzed by flow cytometry to quantify PBL engraftment. Engrafted animals were
infected by I.P. injection of 100 µl HIV- 1ADA using a single dose of 104 tissue culture
infectious doses (TCID50). Twelve hours after infection, mice were injected (I.P.) with 3
mg MVR (in 200 µl solution) and from that point forward, mice were injected (I.P.) with 3
mg of MVR (in 200 µl solution) every 12 hours. Untreated mice were injected (I.P.) with
200 µl of DMSO/PBS solution every 12 hours. Treatment groups were: untreated,
uninfected mice (group G1); treated, uninfected mice (group G2); untreated, infected
mice (group G3); and treated, infected mice (group G4). Animals were bled weekly and
the levels of human cells in animals’ blood quantified by FACS. Animals were sacrificed
at 3 weeks post-infection and tissues from each animal were divided into 3 parts. One
part was used for paraffin embedding and immunohistochemical studies, the second part
was stored in optimal cutting temperature compound for immunofluorescence
experiments, and the third part was used for RNA extraction and qPCR. Uninfected
mice injected with PBS or MVR served as controls.
3.2.3 Flow Cytometry/ Fluorescence-activated cell sorting (FACS)
To quantify human cells in mouse blood, blood samples (approximately 200 µl per
mouse) were collected from the animal facial vein into ethylenediaminetetraacetic acidcoated tubes (BD Biosciences), using lancets (MEDIpoint, Inc., Mineola, NY), before
infection and at 1, 2, and 3 weeks post-infection. Samples were centrifuged at 1800 rpm
for 8 minutes at 4°C to remove serum. Blood samples were brought to a final volume of
50 µl using FACS buffer (PBS containing 2% FBS) and transferred to empty 5 ml
polypropylene round-bottom tubes (BD Falcon, Franklin Lakes, NJ). Any leftover blood
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was mixed in 5 ml polypropylene tubes and used for gating. Blood samples were lysed
by re-suspending in 1 ml Red Blood Cell Lysing Buffer (Roche Diagnostics, Indianapolis,
IN), followed by incubation at room temperature for 5 minutes, and centrifuged at 1500
RPM for 5 minutes. Following centrifugation, the supernatant was discarded and pelleted
cells were resuspended in 1 ml FACS buffer. Fourty microliters of antibody mixture was
then added to each sample and the samples incubated for 1 hour in the dark on ice. The
antibody mixture contained the following fluorochrome-conjugated human monoclonal
antibodies: PE-Cy7 anti-CD45 (Biolegend, San Diego, Ca; product number: 304016),
APC anti-CD8 (Biolegend; 344722), PE anti-CD195 (Biolegend; 321406), Pacific Blue
anti-CD3 (Biolegend; 300330), and FITC anti-CD4 (BD Biosciences; 555346). Following
incubation with antibody, samples were washed twice with 1 ml of FACS buffer by
centrifugation (1500 RPM for 10 minutes) and fixed by resuspension in 200 µl of 2%
paraformaldehyde in PBS. For gating, samples were resuspended in 400 µl of 2% PFA.
Samples were analyzed using a FACS DIVA (BD Immunocytometry Systems, Mountain
View, CA). Results are expressed as percentages of total number of gated lymphocytes.
The gating strategy was human CD45⇒CD3⇒CD4/CD8.
3.2.4 Immunohistochemistry
Following animal sacrifice, each tissue sample was put in a tissue cassette and fixed by
overnight incubation at 4̊ C with PBS containing 4% paraformaldehyde. Tissues were
processed using a Shandon Citadel 1000 automated tissue processor (Thermo Fisher).
Processing consisted of three steps: tissue dehydration, tissue clearing, and tissue
embedding. First, tissues were dehydrated in increasing concentrations of Flex buffer
(Thermo Fisher), a dehydrating agent consisting of a blend of isopropyl and methyl
alcohol. For dehydration, tissues were incubated for 1 hour in a container containing
70% Flex buffer before being transferred to a container containing 80% Flex buffer and
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incubated for 1 hour. This process was repeated for concentrations of 95% and 100%
Flex buffer. After dehydration, tissues were cleared of alcohol using xylene. For
clearing, tissues were incubated in xylene for one hour, transferred to a container
containing fresh xylene and incubated for 1 hour, and transferred once again to another
container containing fresh xylene and incubated for 1 hour. Following dehydration and
clearing, tissues were embedded in paraffin (Leica) by incubation in a container
containing hot paraffin (58̊ C) for 1 hour, transferred to a new container with hot paraffin
(58̊ C), and incubated again for 1 hour.
Tissues were embedded into blocks using a Histostar Embedding Workstation
(Thermo Fisher). To prepare tissue blocks, tissues in cassettes and metal molds were
placed in a 58 °C paraffin bath for 15 minutes. One at a time, a mold and a tissue
cassette was removed from the bath. The mold was filled with a small amount of hot
paraffin and placed on a cold spot for 10 seconds to let the wax harden slightly. With
forceps, the tissue was removed from the cassette, placed into the mold cut side down,
and placed back onto the cold spot. The cassette was placed on top of the mold and hot
paraffin was added to cover the top of the cassette. The mold/cassette was placed on a
cold surface for 30 minutes, more paraffin being added if it seeps below the cover. After
30 minutes the block was popped out of the mold and prepared for cutting.
Tissues were cut using a Leica RM2235 mictrotome. For cutting, paraffin tissue
blocks were placed in the object clamp of the microtome. Excess paraffin was trimmed
from the block at a setting of 20 µM until the tissue was reached. A wipe soaked with
30% ammonia water was placed over the tissue block for 1 minute to soften tissue and
reduce cracking. Five-micrometer sections were cut from the paraffin tissue blocks and
transferred to a 38̊ C water bath containing CitriSolv Hybrid Solvent and Clearing Agent
(Fisher) for 10 to 20 seconds to expand tissue to its original dimensions and to remove
wrinkles. Tissues were mounted onto Fisherbrand Superfrost/Plus microscope slides by
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dipping a slide into the water bath at an angle and gently guiding the tissue onto the
slide with a blunt metal tip. Slides were dried at room temperature overnight on a slide
rack.
For antigen retrieval, slides were dried in an incubator at 60̊ C for 30 minutes and
transferred into a staining dish containing the Trilogy solution (Cell Marque, Rocklin,
CA). The staining dish containing Trilogy/slides along with a second staining dish
containing only Trilogy solution was transferred into a Cuisinart CPC-600 pressure
cooker (East Winsdor, NJ) that was filled with 700 ml water. Slides were incubated in the
pressure cooker for 15 minutes at a pressure of 15 pounds per square inch. After 15
minutes the pressure was removed from the cooker and the slides were transferred to
the second staining dish containing only Trilogy, gently agitated by hand for
approximately 5 seconds, and incubated for 5 minutes while still in the pressure cooker.
Slides were washed five times in a slide dish containing distilled water for 5 minutes
each wash. Finally slides were transferred into a slide dish containing 10% Tween20/trisbuffered saline (TTBS).
For immunohistochemistry, samples were blocked with 10% normal goat serum
(NGS; Vector, Burlingame, CA), diluted in TTBS for 30 minutes in a humidity chamber
(Fisher). Excess NGS was flicked from slides and slides were incubated with a mouse
monoclonal antibody for claudin-5 (1:100; Abcam) diluted in 10% NGS for 1 hour. Slides
were washed 3 times with TTBS, 3 minutes each wash, and then incubated with 1-3
drops of polymer-based HRP-conjugated anti-mouse Dako EnVision secondary antibody
(Carpinteria, CA) for 1 hour in a humidity chamber. Slides were washed 3 times with
TTBS, 3 minutes each wash, and developed with a 3,3’-diaminobenzidine (DAB; Dako).
DAB was prepared by adding 20 µl DAB (1 drop) to 1 ml of the substrate solution
provided. During development, slides were monitored under the microscope for optimal
development time and then rinsed 2 times with deionized water. Slides were
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counterstained with 1:10 dilution of Mayer’s hematoxylin, washed 3 times with water,
dipped in 0.037 mol/l ammonia for 10 seconds, and rinsed with deionized water 3 times.
Slides were dehydrated by incubating two times with 80% ethanol for 5 minutes each
time, two times with 95% ethanol for 5 minutes each time, two times with 100% ethanol
for 5 minutes each time, and three times with 100% xylene for 5 minutes each time.
Slides were mounted by adding a drop of cytoseal 60 (Thermo Fisher) and slowing
placing a coverslip over the tissue to reduce the presence of air bubbles. Omission of
the primary antibodies or use of isotope-matched mouse IgG as primary antibody (Santa
Cruz, Dallas Texas) served as controls. Images were acquired using a Nikon DS-Fi1
camera fixed to a Nikon Eclipse E800 (Nikon Instruments), using NIS Elements F3.0
software. Semi-quantitative analysis of claudin-5 expression (percentage of area
occupied by immunostaining) was performed using computer-assisted image analysis
with Image-Pro®Premier software (MediaCybernetics, Rockville, MD). Three images per
mouse were analyzed.	
  	
  
3.2.5 Immunofluorescence
Mouse brain cortex sections were embedded with OCT in 22 mm X 22 mm X 20 mm
Peel-A-Way embedding molds (Ted Pella Inc, Redding, CA) after sacrifice and stored at
-80 °C until ready to cut. Prior to cutting, embedding molds were warmed slightly to
remove OCT embedded tissue. Five-micrometer sections were cut from each mouse
brain tissue using a Leica CM1860 cryostat and mounted on Fisherbrand
Superfrost/Plus microscope slides. Tissue sections were fixed in 4% paraformaldehyde
diluted in PBS for 20 minutes at room temperature in a humidity chamber, dried, washed
with 1X PBS for 5 minutes at room temperature, and incubated 1 hour in a humidity
chamber with PBS containing 3% BSA to block for non-specific binding. Mouse brain
tissues were incubated overnight at 4 °C in a humidity chamber with ZO-2 antibody (Cell
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Signaling) diluted in PBS containing 3% BSA (1:50 dilution). After incubation with the
primary antibody, slides were washed with 1X PBS 3 times, 5 minutes each wash, and
stained with anti-rabbit secondary antibody coupled with Alexa Fluor-594 (Life
Technologies) diluted (1:500) in PBS containing 3% BSA, for 1 hour in the dark at room
temperature in a humidity chamber. Stained tissues were washed 5 times with 1X PBS,
5 minutes each wash, and mounted with Prolong Gold anti-fade reagent containing DAPI
(Molecular Probes, Grand Island, NY). Stained tissues were examined using an Eclipse
TE20000-U fluorescent microscope (Nikon) with a Cy5 HYQ filter connected to a
CoolSNAP EZ camera (Photometrics, Tucson, AZ). Semiquantitative analysis of ZO-2
expression (percentage of area occupied by immunostaining) was performed by
computer-assisted image analysis using the Image-Pro®Premier software. Three
images per slide were analyzed.
3.2.6 RNA extraction, reverse transcription, and qRT-PCR
Total RNA from mouse brains was extracted using the Trizol reagent. One-milliliter of
Trizol reagent was added to 50 mg of brain tissue and tissues were homogenized using
the TissueRuptor homogenizer (Qiagen, Valencia, CA). Homogenized samples were
incubated at room temperature for 5 minutes and after incubation, 200 µl of chloroform
was added to each sample, shaken by hand for 15 seconds, and incubated at room
temperature for 15 minutes. Samples were centrifuged at 12,000 x g for 15 minutes at
4 ̊C. During centrifugation the mixture separates into three layers: a bottom red phenolchloroform phase, an interphase, and a colorless top aqueous phase. The aqueous
phase was transferred to a new tube and mixed with 500 µl of 100% isopropanol to
precipitate RNA. Samples were incubated at room temperature for 10 minutes followed
by centrifugation at 12,000 x g for 10 minutes at 4 ̊C. Supernatant was removed from the
tubes and 1 ml of 75% ethanol was added to each sample, vortexed, and centrifuged at
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7,500 x g for 5 minutes at 4 ̊C. Supernatant was removed and samples were air dried for
5 minutes at room temperature. Pellets were re-dissolved in 30 µl of RNase-free water
and incubated for 10 minutes on a heat block set at 55 ̊C. RNA was further cleaned
using Total RNA cleanup kit (Qiagen). RNA yield and quality were checked using a
NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE) and for all
samples absorbance ratio of 260/280 was ≥ 2.
Reverse transcription was performed using the Verso cDNA synthesis kit
(Thermo Fisher). One-microgram of RNA in 11 µl of nuclease-free water was mixed with
4 µl 5X cDNA synthesis buffer, 2	
  µl dNTP mix (0.05 mM of each dNTP), 1 µl random
hexamers (400 ng/µl), 1 µl RT enhancer, and 1 µl Verso enzyme mix. Cycling conditions
were: 1 cycle of 42 ̊ C for 30 minutes followed by 95 ̊ C for 2 minutes with a final hold at
4 ̊ C.
Quantitative real-time PCR was performed using a Roche LightCycler 480 II
Roche) with a 384-well block. For each sample, the cDNA obtained was diluted in
nuclease free water at a ratio of 1:20; a 20 µl reaction mixture containing 5 µl of each
diluted cDNA sample, 10 µl of Roche LightCycler 480 Probes master mix (containing the
polymerase enzyme, dNTPs and MgCl2), 4 µl of nuclease free water, and 1 µl of primerprobe [containing 900 nM of each forward and reverse primer and 250 nM TaqMan
minor groove binder (MGB) probe] was prepared. Twenty-microliters of the reaction
mixture was added to the wells of a 384-well plate and loaded into the Roche
LightCycler 480 II machine. Cycling conditions were: 95 ̊ C for 5 minutes with a ramp
rate of 4.8 ̊C/second; followed by 45 cycles of 95 ̊C for 10 seconds with a ramp rate of
4.8 ̊C/second, 60 ̊C for 15 seconds with a ramp rate of 2.5 ̊C/second, and 72 ̊C for 1
second with a ramp rate of 4.8 ̊C/second; and one hold at 40̊ C for 10 seconds with a
ramp rate of 2̊C/second. Data was analyzed as described in 2.2.10. All primers were
obtained from Applied Biosytems. Primer-probe ID or sequences were GAPDH:
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Hs99999905_m1; Long Terminal Repeat (LTR) forward primer: 5′GCCTCAATAAAGCTTGCCTTGA-3′; LTR reverse primer: 5′TCCACACTGACTAAAAGGGTCTGA-3′; LTR probe: 5′-FAMGCGAGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGCTCGC-MGB-3′; Tat forward
primer: 5′-GGAGGAGGGTTGCTTTGATAGAG-3′; Tat reverse primer: 5′AAAGCCTTAGGCATCTCCTATGG-3′; and Tat probe: 5′-FAMCTTCGTCGCTGTCTCCGCTTCTTCC-MGB-3; Pol forward primer: 5′GCACTTTAAATTTTCCCATTAGTCCTA-3′; Pol reverse primer: 5′CAAATTTCTACTAATGCTTTTATTTTTTC-3′; Pol probe: 5′-FAM-	
  
AAGCCAGGAATGGATGGCC-MGB-3′.

3.2.7 Ultraperformance liquid chromatography tandem mass spectrometry (UPLCMS/MS)
NSG mice not engrafted with human-PBL were used to quantify levels of MVR in mouse
plasma and brain samples. Mice were mice were injected (I.P.) with 3 mg MVR (in 200 µl
solution) every 12 hours for three weeks. After 3 weeks of treatment, mice were
sacrificed and blood and tissue samples were collected as described in 3.2.2. To
quantify MVR levels in plasma, 50 µl of plasma was added to 10 µl of 1 µg/ml indinavir
(IDV) free base as internal standard (IS) and 1 ml of ice-cold acetonitrile. For brain
tissue, 100 mg of tissues was homogenized in 4 volumes of UPLC-grade water and then
added to 10 µl of IS and 1 ml ice-cold acetonitrile. Both plasma and brain samples were
vortexed for 3 minutes and centrifuged at 16,000 x g for 10 min at 4˚C. One milliliter of
supernatant was evaporated to dryness under vacuum and dried samples were
reconstituted in 100 µl of 50% UPLC-grade methanol diluted in water. The samples were
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centrifuged for 10 min at 16,000 x g at 4˚C and 40 µl of supernatant was used for
analysis.
Chromatographic separation was performed using a Waters ACQUITY UPLC
(Milford, MA) system coupled with AB 4000 Q TRAP quadruple linear ion trap hybrid
mass spectrometer, with an electrospray ionization source (Applied Biosystems/MDS
Sciex, Foster City, CA). Separation was achieved using an Acquity BEH Shield RP18
column (1.7 µm, 2.1 x 100 mm) equipped with an Acquity VanGuard BEH Shield
precolumn (1.7 µm, 2.1 x 5 mm) using a step-wise gradient of 7.5 mM ammonium
acetate, pH 5 for mobile phase A and acetonitrile for mobile phase B. The gradient was
held at 70% mobile phase A for 3 minutes, decreased to 40% mobile phase A over 1
minute and 30 seconds and held for 30 seconds, decreased to 5% mobile phase A over
30 seconds and held for 30 seconds, increased to 70% mobile phase A over 15 seconds
and held for 1 minute and 45 seconds prior to next sample injection at a flow rate of 0.25
ml/min. The injection volume for all samples was 10 µl. Detection was achieved in the
positive ionization mode using the following transitions: m/z MVC 514/280; m/z IDV
614/421. Calibration standards consisted of 0.2 to 2000 ng/ml MVR with 100 ng/ml IDV
for both plasma and brain homogenates and the ratio of analyte to IS peak area was
used for quantitation of unknowns.
3.2.8 Statistical analysis
Statistical analysis was performed as described in section 2.2.11.
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3.3 Results
3.3.1 MVR treatment or HIV-1 infection does not affect hu-PBL NSG mouse
weights
To assess the effect of MVR treatment and HIV-1 infection on the weights of hu-PBL
NSG mice, we weighed mice every four days during the course of the experiment. All
groups: untreated, uninfected (G1; N=5); treated, uninfected (G2; N=10); untreated,
infected (G3; N-12); and treated, infected (G4; N=12) lost weight during the treatment
period, but weight changes during the course of treatment was not significantly different
among the four groups of mice (Figure 3-2).
3.3.2 HIV-1 infection decreased human CD4+ cells and increased CD8+ cells in the
blood of HIV-1-infected hu-PBL NSG mice and treatment with MVR attenuated
these effects
HIV-1 infection is known to decrease the level of CD4+ cells and increase the levels of
CD8+ [267]. To this end, we analyzed animal’s blood samples at weeks 1, 2, and 3 p.i.
by FACS to determine whether MVR treatment of infected mice could restore these cells
to normal levels. There was no significant difference in human CD4+ or human CD8+
cell levels at week 1 p.i. between any of the 4 groups (Figure 3-3, 3-4). FACS analyses
showed that human CD4+ cell levels decreased by 4.1-fold (p<0.001) and 14.4-fold
(p<0.001) in placebo-treated infected mice compared to placebo-treated uninfected mice
at weeks 2 and 3 p.i., respectively (Figure 3-3). Similar results were observed in
placebo-treated infected mice compared to MVR-treated uninfected mice, with human
CD4+ cell levels decreasing by 3.9-fold (p<0.001) and 14.7-fold (p<0.001) at weeks 2
and 3 p.i., respectively (Figure 3-3). MVR-treated infected mice showed an increase in
human CD4+ cell levels by 2.3-fold (p<0.05) compared to placebo-treated infected mice
at week 2 p.i. (Figure 3-3). There was no significant difference in human CD4+ cell levels
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in MVR-treated infected mice compared to placebo-treated infected mice at week 3 p.i.
(Figure 3-3).
Human CD8+ cell levels increased by 1.8-fold (p<0.001) and 3.0-fold (p<0.001)
in placebo-treated infected mice compared to placebo-treated uninfected mice at weeks
2 and 3 p.i., respectively (Figured 3-4). Similar results were observed in placebo-treated
infected mice compared to MVR-treated infected mice, with human CD8+ cell levels
increasing by 1.7-fold (p<0.001) and 3.1-fold (p<0.001) at weeks 2 and 3 p.i. (Figure 34). MVR-treated infected mice showed a decrease in human CD8+ cell levels by 1.24fold (p<0.05) compared to placebo-treated infected mice at week 3 p.i. (Figure 3-4).
There was no significant difference in human CD8+ cell levels in MVR-treated infected
mice compared to placebo-treated infected mice at week 3 p.i. (Figure 3-4).
3.3.3 HIV-1 infection decreases the levels of CD45+ cells in the blood of hu-PBL
NSG mice and MVR treatment attenuates this effect
CD45 is a transmembrane protein found on the surface of all differentiated
hematopoietic cells, except red blood cells and effector B cells [268]. We used FACS to
estimate the levels of human CD45+ cells in animal’s blood samples. There was no
significant difference in human CD45+ cell levels at week-1 p.i. between any of the four
groups (Figure 3-5). Human CD45+ cell levels decreased by 1.5-fold (NS) and 2.2-fold
(p<0.05) in placebo-treated infected mice compared to placebo-treated uninfected mice
at weeks 2 and 3 p.i., respectively (Figure-3-5). Similar results were observed in
placebo-treated infected mice compared to MVR-treated uninfected mice, with human
CD45+ cell levels decreasing by 1.5-fold (NS) and 2.1-fold (p<0.05) at weeks 2 and 3
p.i., respectively (Figure 3-3). MVR-treated infected mice showed a 2-fold increase in
human CD45+ levels compared to placebo-treated infected mice at both weeks 2 and 3
p.i. (p<0.01, Figure 3-5).
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3.2.4 HIV-1 infection disrupts claudin-5 and ZO-2 in the brain microvasculature of
hu-PBL NSG mice and MVR prevents HIV-1-induced vascular damage
HIV-1 infection is associated with disruption of the BBB. Endothelial cells are a major
component of the BBB. Endothelial cells are connected together by tight junctions that
prevent the passive diffusion of materials between cells [154]. Claudin-5 is a major
component of the BBB that plays a role in maintaining its integrity [269, 270]. ZO-2 is
found at the cell membrane and acts as molecular scaffolds at the cytoplasmic side of
tight junctions [271]. HIV-1 infection is associated with decreased expression of Claudin5 and ZO-2 [272]. We have previously showed that CCR5 antibodies can partially
prevent HIV-1-induced activation of STAT1 and STAT3 in HBMEC [215, 216]. Activation
of STAT1 and STAT3 in HBMEC results in inflammation that leads to the loss of tight
junctions [215, 216]. To determine whether blocking CCR5 in vivo in NSG mice
attenuates HIV-1-induced vascular damage, we performed immunostaining for claudin-5
and ZO-2. HIV-1 infection resulted in injury to the brain endothelium, evidenced by loss
of immunostaining for claudin-5 and ZO-2 (Figure 3-6A, B). Claudin-5 expression
decreased by 1.7-fold in placebo-treated infected mice compared to placebo-treated
uninfected mice and decreased by 1.3-fold in placebo-treated infected mice compared to
MVR-treated uninfected mice (Figure 3-6A). MVR-treated infected mice showed a 2.3fold increase in claudin-5 expression compared to placebo-treated infected mice
(p<0.05, Figure 3-6A). ZO-2 expression decreased by 1.5-fold in placebo-treated
infected mice compared to placebo-treated uninfected mice and decreased by 1.4-fold in
placebo-treated infected mice compared to MVR-treated uninfected mice (Figure 3-6B).
MVR-treated infected mice showed a 1.5-fold increase in ZO-2 expression compared to
placebo-treated infected mice (p<0.01, Figure 3-6B).
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3.3.5 MVR reduced HIV-1 levels in the brains of hu-PBL NSG mice
HIV-1-infected patients treated with MVR have decreased viral loads in their CSF [121,
124, 125, 273]. However, no study to date has investigated whether MVR can reduce
viral loads in the CNS. To examine if MVR treatment could reduce HIV-1 levels in the
brains of infected mice, we quantified HIV-1 Tat, LTR, and pol by real-time PCR using
mRNA isolated from mice brains. Tat mRNA levels was increased by 6.9-fold (p<0.01) in
the brains of infected mice compared to placebo-treated or MVR-treated uninfected mice
and MVR treatment of infected mice decreased Tat mRNA levels by 3.5-fold (p<0.05)
compared to placebo-treated infected mice (Figure 3-7A). HIV-1 infection increased LTR
mRNA levels by 12,753-fold (p<0.001) compared to placebo-treated or MVR-treated
uninfected mice and MVR treatment of infected mice decreased LTR mRNA levels by
11.5-fold (p<0.05) compared to placebo-treated infected mice (Figure 3-7B). Pol mRNA
expression was increased by 10.6-fold (p<0.001) in infected mice compared to untreated
or treated uninfected mice and MVR treatment of infected mice decreased pol mRNA
levels by 10.8-fold (p<0.001) compared to placebo-treated infected mice (Figure 3-7C).
3.3.6 MVR is detectable in the CNS of NSG mice
Detectable levels of MVR in the CSF have been shown in multiple studies, with levels
above the protein-adjusted inhibitory concentration (IC50) of 0.57 ng/ml [121, 123-125].
However no studies have quantified MVR concentrations directly in the CNS. To this
end, we quantified MVR concentrations in the brains of 8 mice treated with MVR twice
daily for 3 weeks using UPLC-MS/MS. All mice had quantifiable CNS levels of MVR with
a mean of 217 ng/g (range: 81 - 685 ng/g) (Table 3-1). MVR was also detectable in the
plasma of all mice, with a mean plasma concentration of 117 ng/ml (range: 7.23 ng/ml –
294 ng/ml). There was a weak positive correlation (r = 0.41) between plasma and brain
MVR concentrations.
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3.4 Discussion
Using a mouse model of HIV/AIDS, we showed that HIV-1 decreased the levels of
human CD4+ cells and CD45+ cells and increased the levels of CD8+ cells in the blood
of engrafted mice. Treatment with MVR attenuated HIV-induced destruction of CD4+ and
CD45+ cells. We further demonstrated that blocking CCR5, via the antagonist MVR,
reduced HIV-1-induced BBB injury. We found reduced levels of claudin-5 and ZO-2
expression in the brain vasculature of HIV-1-infected mice and treatment with MVR
diminished HIV-1-induced downregulation of claudin-5 and ZO-2. Lastly we showed that
MVR treatment reduced HIV viral loads in the brain and that MVR was quantifiable in the
CNS.
Tight junctions are components of the BBB that restrict the passage of molecules
into the CNS [154]. Claudins are one of the most integral components of tight junctions
and regulate the paracellular permeability of the barrier [274]. Claudin-5 is highly
expressed in endothelial cells of the BBB and is the main structural transmembrane
component of tight junctions [154, 275, 276]. Our results showing that HIV-1 infection
decreases claudin-5 expression in the brain vasculature is consistent with other studies
involving HIV-1 and/or HIV-1 proteins. Tat decreased claudin-5 expression and induced
cellular redistribution of claudin-5 immunoreactivity in primary HBMEC, and this
decrease was associated with monocyte infiltration into the brain tissues [174]. Claudin-5
expression was also decreased by direct exposure of HBMEC to HIV-1 [216].
Furthermore, Claudin-5 expression was decreased in brain microvessels of HIV-1infected individuals with HAD [216]. Gp120 decreased claudin-5 expression when
injected directly into the caudate putamen of rats [189].
ZO proteins act as scaffolding proteins to connect tight junction proteins to the
actin cytoskeleton [154, 271]. ZOs bind directly to claudins on their N-terminal side via
their PDZ domain and interact with actin on their C-terminal side [271]. ZO-2 is found in
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brain endothelial cells [271]. In our mouse model of HIV/AIDS we showed that ZO-2 was
decreased during HIV-1 infection. Studies have shown that Tat and gp120 exposure
results in decreased ZO-2 expression in HBMEC [174, 178, 180].
HIV-1- and HIV-1 protein-induced decrease of claudin-5 and ZO-2 expression
can occur via the Ras/ERK1/2 pathway through activation of vascular endothelial growth
factor receptor type 2 (VEGFR-2) [36]. The PI3K/protein kinase B (PKB) pathway and
STAT/janus kinase (JAK) pathway are also involved [216, 277]. In fact, there is cross
talk between the PI3K/PKB pathway and STAT/JAK pathway in HIV-1-induced
endothelial dysfunction and this is partially mediated by CCR5 [215, 278]. Posttranslational modifications (PTMs) of tight junction proteins have been found to be
associated with disruption of the BBB [279, 280]. Claudin-5 is phosphorylated by
activation of the Rho GTPase, Rho, and its downstream enzyme Rho-associated protein
kinase (RhoK), which leads to increased HIV-1-induced monocyte migration through
HBMEC and BBB disruption [280]. It is therefore possible that HIV-1 binding to CD4
and/or CCR5 or CXCR4 can activate small GTPases, such as Ras and Rho, which in
turn activate the PI3K/AKT, STAT/JNK, and/or ERK1/2 pathways, resulting in PTM of
tight junction proteins and BBB dysfunction.
HBMEC express CCR5 and it has been suggested that gp120 can bind directly
to CCR5 and induce BBB dysfunction [179]. Furthermore, our data showed that HIVinduced BBB disruption was reduced by MVR treatment. This suggests that MVR could
not only attenuate HIV-induced BBB dysfunction by preventing HIV entry into
monocytes/macrophages and T-cells, but also possibly by directly preventing the binding
of HIV-1 proteins (i.e. Tat and gp120) to brain endothelial cells; reducing tight junction
disruption by blocking the activation of VEGFR-2 and the PI3K/AKT and STAT/JAK
pathways; or by reducing monocyte infiltration into brain tissues.
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Many antiretroviral drugs are not able to penetrate the CNS, and thus, the brain
remains an HIV reservoir [281, 282]. Therefore, drugs that are able to pass through the
BBB could help in the elimination of viral reservoirs. The CNS HIV Antiretroviral Therapy
Effects Research group ranks drugs on the basis of information from the literature on
measured CSF concentrations, physiochemical drug characteristics, and effectiveness in
the CNS (reflected by suppression of CSF viral load and improved neurocognitive
performance) [10, 283]. Drugs are given a CNS penetration-effectiveness rank, with 4
having the highest estimated CNS penetration and 1 having the lowest [283]. MVR has
a ranking of 3, suggesting that it is able to penetrate the CNS [283]. This ranking is
based on several studies showing detectable levels of MVR in the CSF, with levels
higher than the protein-adjusted IC50 of 0.57 ng/ml [121, 123-125, 273]. In agreement
with these data, we found that mice had quantifiable CNS levels of MVR, with a mean of
217 ng/g (range: 81 ng/g - 685 ng/g).
MVR was first discovered to be a substrate for Pgp1, which suggested limited
CNS penetration [97]. MVR was later found to be a substrate for organic anion
transporting polypeptide 1B1 (OATP1B1) [284]. OATPs are a superfamily of influx
transporters that generally transport large and hydrophobic organic anions [285]. All
OATPs share a similar transmembrane domain organization, with 12 predicted
transmembrane domains and a large fifth extracellular loop [286]. OATP1B1 is mainly
expressed in the liver, but has also been detected in small intestinal enterocytes [287,
288]. It does not appear to be expressed in cells of the brain or cells of the BBB [289,
290]. It is possible that other OATPs could be involved in the transport of MVR into the
brain, such as OATP1A2, which has been found be highly expressed in the brain [291,
292]. OATPs that are within the same family, such as the OATP1 family, share ≥40%
amino acid sequence similarity and may share substrates; for example, HIV-1 protease
inhibitors have been shown to be substrates for both OATP1A2 and OATP1B1 [291,
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293]. In addition to OATPs, other families of influx transporters include organic anion
transporters, organic cation transporters, and peptide transporters [285, 294].
In addition to showing that MVR can be quantified in the brain, we also showed
that MVR reduced HIV-1 Tat, LTR, and pol levels in the brain. This is consistent with
studies showing that MVR can reduce HIV-1 infection in the CSF [123, 124].
Additionally, MVR has been shown to reduce SIV RNA and DNA levels in the brains of
rhesus macaques [265]. However, short-term MVR intensification in HIV-1-infected
individuals on cART was not associated with improvements in neurologic assessments
[295]. Conversely, patients with HIV-1-associated neurocognitive impairment treated
with a combination of abacavir, lamivudine, and MVR for 48 weeks showed a trend
towards neurocognitive improvement [217]. In another study, when MVR was added to
patients cART regimens, patients showed significant cognitive improvements [296]. Our
data showing that MVR can enter the CNS and reduce brain viral loads in mice, taken
together with the above data showing that long term MVR treatment in humans is
associated with neurocognitive improvements, provides evidence that MVR is a viable
option for the treatment of HAND.
One of the hallmarks of HIV-1 infection is the loss of CD4+ T-cells and an initial
increase of CD8+ T-cells [267, 297, 298]. Our data was consistent with these changes,
as we saw a decrease in human CD4+ cells and an increase in human CD8+ cells in
placebo-treated HIV-1-infected mice. HIV-1-infected mice that were treated with MVR
had at least a partial attenuation of these changes. In HIV-1-infected patients, MVR has
been associated with improvements in T-cell counts and our data is consistent with
these reports [128]. In addition, we observed a decrease in the levels of human CD45+
cells in placebo-treated HIV-1-infected mice. HIV-1-infected mice that were treated with
MVR had a partial increase in CD45+ cell levels. CD45 is a protein tyrosine phosphatase
that is expressed on all nucleated hematopoietic cells and is involved in T-cell
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development and signaling [268]. HIV-1 infection results in dysfunction of CD45
signaling [299]. These results suggest that MVR is able to at least partially restore
balance to the immune system, which could help in further suppression of viral load.
Overall, MVR was safe, as observed by no significant differences in weights
among animals groups. MVR restored the level of immune cells in infected animals,
increasing CD4+ and CD45+ cells and decreasing CD8+ cell levels. Furthermore, MVR
was able to reduce the severity of HIV-1-induced BBB injury by preventing the
downregulation of the tight junction proteins claudin-5 and ZO-2. Finally, we showed that
MVR can enter the CNS and can decrease infection in the brain. Our results suggest a
potential role for MVR in decreasing viral reservoir in the brain and reducing the severity
and prevalence of HAND.
3.5 Summary
To elucidate the role of CCR5 inhibition/MVR on HIV-1-induced BBB dysfunction and
CNS infection we used a mouse model of HIV-1/AIDS. We used immunohistochemistry
and immunofluorescence to show that HIV-1 infection results in disruption of the tight
junction proteins, claudin-5 and ZO-2. Tight junction disruption was at least partially
attenuated in infected mice treated with MVR. Using FACS analysis, we showed that
HIV-1 infection of mice decreased CD4+ cells and CD45+ cells and increased CD8+
cells in blood plasma, and MVR treatment of infected mice had a partial attenuation of
these changes. Quantitative real-time-PCR on mRNA isolated from brain tissue showed
that MVR treatment reduced HIV-1 viral load in the CNS. MVR levels were quantified in
the blood plasma and brains of mice using UPLC-MS/MS. Mice treated with MVR over
the course of 3 weeks had detectable levels of MVR in their brains and plasma.
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3.6 Figures and tables

Figure 3-1: The Hu-PBL NSG mouse model. NSG mice (4 to 6 weeks old) were
injected with 30 million of human PBL (Day -14). One week later, mice were bled
through the facial vein and blood was analyzed by FACS to confirm engraftment of
human immune cells (Day -7). At day 0, mice were infected with HIV-1ADA, and 12 hours
after infection injected with MVR (3 mg I.P.) or PBS. Mice were treated with MVR or PBS
twice a day (about every 12 hours). Once a week mice were bled and blood samples
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were analyzed by FACS to quantify the levels of human immune cells. At day 21, mice
were sacrificed and tissue and blood samples collected for further analysis.
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Figure 3-2: MVR or HIV-1 infection does not affect the weights of Hu-PBL NSG
mice. NSG mice were engrafted with 30 million human PBL/mouse and infected with
HIV-1ADA (104 TCID50). Mice were weighed every four days during the course of the
experiment. The mean weight of each group from day 0 through day 20 is shown.
Circles: control mice (G1), squares: uninfected mice treated with MVR (G2), triangles:
HIV-1 infected mice (G3), upside-down triangles: HIV-1 infected mice treated with MVR
(G4). Number of mice in each group: G1: 5, G2: 7, G3: 12, G4: 12. Two-way ANOVA
followed by Bonferroni’s correction for multiple-comparisons was performed using
GraphPad Prism 5.0b to determine significance. Threshold of significance level was
0.05. Error bars represent mean ± SEM.
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Figure 3-3: Levels of CD4+ cells in the blood of HIV-1-infected Hu-PBL NSG mice.
NSG mice were engrafted with 30 million human PBL/mouse and infected with HIV-1ADA
(104 TCID50). Engrafted mice were treated with MVR (3 mg/mouse) or PBS twice daily.
Mice were bled weekly and the levels of CD4+ in the blood were determined by FACS
analysis. One-way ANOVA followed by Tukey’s post-test for multiple-comparisons was
performed using GraphPad Prism 5.0b to determine significance. Threshold of
significance level was 0.05. Error bars represent mean ± SEM. *p ≤ 0.05, ***p ≤ 0.001.
Number of mice in each group: G1 (uninfected mice): 5, G2 (uninfected mice treated
with MVR): 7, G3 (infected mice): 12, G4 (infected mice treated with MVR): 12	
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Figure 3-4: Levels of CD8+ cells in the blood of HIV-1-infected Hu-PBL NSG mice.
NSG mice were engrafted with 30 million human PBL/mouse and infected with HIV-1ADA
(104 TCID50). Engrafted mice were treated with MVR (3 mg/mouse) or PBS twice daily.
Mice were bled weekly and the levels of CD8+ in the blood was determined by FACS
analysis. One-way ANOVA followed by Tukey’s post-hoc test for multiple-comparisons
was performed using GraphPad Prism 5.0b to determine significance. Threshold of
significance level was 0.05. Error bars represent mean ± SEM.*p ≤ 0.05, ***p ≤ 0.001.
Number of mice in each group: G1 (uninfected mice): 5, G2 (uninfected mice treated
with MVR): 7, G3 (infected mice): 12, G4 (infected mice treated with MVR): 12
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Figure 3-5: Levels of CD45+ cells in the blood of HIV-1-infected of Hu-PBL NSG
mice. NSG mice were engrafted with 30 million PBL/mouse and infected with HIV-1ADA
(104 TCID50). Engrafted mice were treated with MVR (3 mg/mouse) or PBS twice daily.
Mice were bled weekly and the levels of CD45+ in the blood was determined by FACS
analysis. One-way ANOVA followed by Tukey’s post-hoc test for multiple-comparisons
was performed using GraphPad Prism 5.0b to determine significance. Threshold of
significance level was 0.05. Error bars represent mean ± SEM. *p ≤ 0.05, **p ≤ 0.01.
Number of mice in each group: G1 (uninfected mice): 5, G2 (uninfected mice treated
with MVR): 7, G3 (infected mice): 12, G4 (infected mice treated with MVR): 12
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Figure 3-6. MVR treatment prevents HIV-1-induced disruption of CNS tight
junctions in HIV-1-infected of Hu-PBL NSG mice. NSG mice were engrafted with 30
million human PBL/mouse. Engrafted mice were infected with HIV-1ADA at 104 TCID50.
and/or treated with MVR (3 mg/mouse) twice daily, sacrificed at week-3 p.i., and brain
tissues collected. To determine if MVR treatment could prevent HIV-1-induced CNS
injury, tight junction protein expression on mice brain tissue sections was examined by
immunohistochemistry and immunofluorescence, and three sections per sample were
analyzed. Claudin-5 and ZO-2 expression was quantified by semi-quantitative analysis
using the Image Pro-Premier software. A: immunohistochemistry of claudin-5, B: semiquantitative analysis of claudin-5 staining, C: immunofluorescence of ZO-2. D: semiquantitative analysis of ZO-2 staining. One-way ANOVA followed by Tukey’s post-hoc

	
  

	
  

	
  

	
  

110	
  	
  

test for multiple-comparisons was performed using GraphPad Prism 5.0b to determine
significance. Threshold of significance level was 0.05. Error bars represent mean ±
SEM. Significance *p ≤ 0.05. Number of mice in each group: G1 (uninfected mice): 5, G2
(uninfected mice treated with MVR): 7, G3 (infected mice): 12, G4 (infected mice treated
with MVR): 12
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Figure 3-7. MVR reduces HIV-1 levels in the brains of Hu-PBL NSG mice. NSG mice
were engrafted with 30 million human PBL/mouse and infected with HIV-1ADA (104
TCID50). Engrafted mice were treated with MVR (3 mg/mouse) or PBS twice daily,
sacrificed at week-3 p.i., and brain tissues collected. RNA was extracted from brain
tissues and used for real-time PCR to quantify the expression of HIV-1 genes. The levels
of Tat (A), LTR (B) and pol (C) RNA in brains were quantified by real-time PCR using the
delta Ct method, and normalized to each sample’s human GAPDH. One-way ANOVA
followed by Tukey’s post-hoc test for multiple-comparisons was performed using
GraphPad Prism 5.0b to determine significance. Threshold of significance level was
0.05. Error bars represent mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Number of
mice in each group: G1 (uninfected mice): 5, G2 (uninfected mice treated with MVR): 7,
G3 (infected mice): 12, G4 (infected mice treated with MVR): 12.

	
  

	
  

	
  

	
  

	
  
Mouse
1

MVR Serum
concentrations
(ng/ml)
7.23

MVR Brain
concentrations
(ng/g)
91.5

2

31.2

89

3

17

81

4

49.6

98

5

52.8

96

6

294

105

7

254

487.5

8

234

685

Table 3-1: MVR concentrations in the serum and brains of mice.
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Chapter 4
Conclusions
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4.1 Conclusions and future directions
4.1.1 Chapter 2
In this study we used a combination of in vivo and in vitro techniques to help elucidate
the role of CCR5 in HIV-1-induced BBB dysfunction and HAND. We found that CCR5
blockers could diminish HIV-1 infection in MDM and HIV-1-induced monocyte adhesion
to the BBB. This is in agreement with other studies showing that treatment with MVR
could prevent monocyte, macrophage, and HIV-1-induced T-cell chemotaxis in vitro
[224, 266]. In addition, CCR5 blockers did not disrupt endothelial integrity. This suggests
that they will not induce BBB dysfunction on their own.
We used a cytoskeleton-associated protein array and found that expression of
cytoskeleton-associated proteins was upregulated in HIV-1-infected monocytes following
monocyte-endothelial communications, including Rac1, cortactin, and ERK1/2.
Treatment with CCR5 antagonists prevented these changes. We further found that Rac1
and cortactin mRNA expression is upregulated in the brains of HIV-1-infected individuals
compared to seronegative controls and individuals with HIVE; and phosphorylation of
Rac1 at S71 is upregulated in the brains of HIV-1-infected individuals compared to
seronegative controls and individuals with HIVE. Since RAC1 and cortactin was
upregulated in HIV-1-infected patients without evidence of encephalitis and not HIV-1infected patients with encephalitis, we suggest that HIV-1-induced transcriptional
regulation of Rac1 and cortactin likely occurs during the earlier stages of infection; this
correlates with BBB breach and increased cell trafficking into the CNS. We used
immunofluorescence analysis to determine the location of pRac1 (S71) in the human
brain. We found that pRac1 (S71) is expressed mostly in brain macrophages and blood
vessel tight junctions; expression in microglia was limited to a few samples from
individuals with HIVE and there was no expression in astroglia and neurons.
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Rac1 is involved in cellular adhesion and migration through the formation of
membrane ruffles and lamellipodia [245, 300]. Therefore, it was not surprising to see
Rac1 upregulated in monocytes during monocyte-endothelial communications. The
possibility of Rac1’s involvement in HIV-1-induced adhesion of monocytes to the BBB is
in agreement with studies showing that activation of Rac1 in lymphocytes promotes
adhesion by cell spreading [247]. Rac1 has already been implicated in HIV-1
pathogenesis. It can interact with Nef to cause cytoskeletal rearrangements and
increased lamellipodia formation, it can help in translocating Tat through cell
membranes, and can promote viral particles production [235-237, 253]. Furthermore,
Rac1 can be activated through CCR5 to promote cytoskeletal rearrangements [221].
Future experiments will be to elucidate the pathway through which CCR5 induces Rac1
activation in HIV-1 infected monocytes. Other future experiments will include using a
Rac1 inhibitor to determine whether Rac1 inhibition alone can prevent HIV-1-induced
monocyte adhesion to the BBB.
4.1.2 Chapter 3
We next used a hu-PBL mouse model to examine the in vivo effects of CCR5 inhibitors
during HIV-1 infection. We used the CCR5 antagonist MVR, since it is currently used to
treat HIV-infected humans in clinical settings. As expected, we saw a loss of CD4+ cells
and an increase in CD8+ cells in the blood of mice following HIV-1 infection. Treatment
with MVR could partially attenuate these changes. This is in agreement with several
studies showing that MVR treatment is associated with increases in CD4+ cell levels
[128, 129, 301]. We also showed that HIV-1 infection reduced the levels of CD45+ cells
in the blood and treatment with MVR helped restore these levels. These results suggest
that MVR could help restore the immune cells and immune function in HIV-1 infection.
Immune restoration in the periphery could be beneficial for the integrity of the BBB and
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the prevention of HAND. By decreasing infection levels in the periphery there would be
less infected cells entering into the CNS, thus decreasing the levels of CNS
inflammation.
Next, using our mouse model we examined the expression of tight junction
proteins in the brain following HIV-1 infection and MVR treatment. Using
immunofluorescence and immunohistochemistry analyses, we showed that the levels of
claudin-5 and ZO-2 were reduced in the brains of HIV-1-infected mice. These results are
in agreement with several studies showing that HIV-1 infection and HIV-1 proteins can
diminish the expression of tight junction proteins [176, 178, 180, 272, 277, 302]. MVR
treatment was able to partially attenuate the loss of claudin-5 and ZO-2. It is not known
whether this attenuation was through the inhibition of HIV-1 infection or if MVR can
directly prevent these changes. It is likely a combination of both. It has been shown that
gp120 can bind to CCR5 without binding CD4 on HBMEC and that this resulted in BBB
dysfunction [179, 215]. Therefore it is likely that MVR could prevent viral protein binding
to endothelial cells, thus preventing viral-induced endothelial dysfunction. Pathways that
are involved in BBB disruption, such as ERK1/2 pathway, PI3K pathway, and the STAT
pathway, have been found to be activated by CCR5 [215, 216, 303]. Furthermore, PTM
of tight junction proteins are associated with BBB dysfunction and these PTM occurred
through activation of Rho GTPases [279, 280]. Future studies will include further
elucidating the role of CCR5 in HIV-1-induced BBB dysfunction, and determine whether
this involves PTM of tight junction proteins. We will also determine if Rac1 activation
during HIV-1 infection is associated with BBB dysfunction.
We showed that MVR treatment of HIV-1-infected mice decreased Tat, LTR, and
pol mRNA in the brain. This is in agreement with studies showing that MVR treatment
decreases viral load in the CSF [123, 125]. We then showed, using UPLC-MS/MS, that
MVR was detectable in the brains of mice. This is in agreement with studies showing
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that MVR is detectable in the CSF at levels higher than its IC50 [121, 123-125, 273].
Future studies will elucidate how MVR enters the brain. MVR is a known substrate of
Pgp1, which is involved in drug efflux [97, 304]. Pgp1 is a substrate for many
antiretrovirals and can prevent the accumulation of these drugs into sanctuary sites,
such as the brain [305]. MVR has also been shown to be a substrate for OATP1B1,
which is involved in drug influx [284, 285]. However, this transporter does not appear to
be expressed in the brain or in cells of the BBB [285]. It is possible that MVR could be
transported across the BBB through another member of the OATP1 family that is
expressed in cells of the BBB.
4.2 Overall summary
Our data suggest that MVR could reduce HAND by reducing viral infection of
macrophages, decreasing monocyte infiltration into the brain, reducing brain viral loads,
and preventing HIV-induced tight junction down-regulation. However, our studies did not
examine neurocognitive impairment in animals. A few studies have looked at the effect
of MVR on neurocognitive impairment using both simian models and human patients.
Fourteen-day treatment intensification with 150 mg/kg of MVR twice daily in HIV-infected
neurologically asymptomatic adults resulted in a small increase in markers of neuronal
integrity [122]. SIV-infected rhesus macaques treated with MVR showed decreased CNS
levels of SIV RNA and DNA, decreased inflammation, macrophage activation, and
amyloid precursor protein [265]. Neurocognitively impaired HIV-infected patients
receiving MVR trended towards improvements in neurocognitive status and showed
reduced CNS inflammation [217]. MVR intensification was associated with significant
improvements in neuropsychological performance in patients with mild to moderate
neurocognitive impairment [296].
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Our studies suggest a role for CCR5 in HIV-1-induced BBB disruption. We
propose the following overall mechanism for the possible role of CCR5 in HIV-1-induced
BBB disruption: HIV-1 infection of monocytes results in cytoskeleton changes, via
activation of cytoskeletal-associated proteins, such as Rac1 and cortactin, that leads to
increased adhesion and migration of these infected monocytes through the brain
endothelium. Increased migration of infected cells results in BBB injury and CNS
infection; and inflammation in the brain results in reduced expression of BBB tight
junctions, which further increases the infiltration on infected cells into the CNS, as well
as allowing free viral particles to enter the CNS. Free virus infiltrating into the CNS leads
to increased levels of infection and inflammation in the brain, resulting in neuronal
damage and eventual neuronal death.
One must consider the possible negative consequences of blocking CCR5.
CCR5 has a neuroprotective role during infection with West Nile Virus, as it enhanced
the leukocytes trafficking into the CNS and helped in WNV clearance [42]. In addition to
its role in HIV CNS infection and subsequent neurocognitive impairment, CCR5 has also
been shown to have some neuroprotective effects during HIV-1 infection. CCL4 and
CCL5 can out-compete gp120 for binding to CCR5 activation of CCR5 can activate the
AKT pathway in microglia, neurons, and astrocytes, and provide protection against HIVinduced neurotoxicity and neuronal death [197, 306, 307]. One must also consider the
effects of aging and other antiretrovirals on neuronal health. Low, but otherwise
detectable, levels of HIV RNA can be found in the CSF in 10% of patients on long-term
cART with undetectable plasma viral load [308]. The effect of this low level of RNA
remains unforeseen. In addition, long-term use of ART is associated with numerous
adverse effects, including hepatic steatosis, neuropathy, and cardiomyopathy [309].
In conclusion, in this study, we determined that CCR5 inhibition could prevent
MDM infection and HIV-1-induced monocyte adhesion to the BBB. This was associated
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with increased expression and phosphorylation of the cytoskeleton-associated protein
Rac1, which is involved in cellular adhesion and migration, in monocytes. CCR5
inhibition also prevented these changes. Rac1 mRNA expression was increased in the
brains of HIV-1-infected individuals compared to seronegative controls and individuals
with HAND. There was also increased expression of pRac1 (S71) in the brains of
infected individuals compared to seronegative controls and individuals with HAND.
Expression of pRac1 (S71) in the brain is limited mainly to brain macrophages and blood
vessel tight junctions. MVR treatment in HIV-1-infected hu-PBL NSG mice partially
prevented HIV-1-induced decreases of CD4+ levels and CD45+ levels and HIV-1induced increase of CD8+ cells. MVR partially attenuated the loss of tight junction
proteins in infected mice. MVR decreased viral loads in the brain of infected mice and
MVR could be quantified in the brains of mice. Taken together, these results suggest a
role for CCR5 in the pathogenesis of BBB dysfunction during HIV-1 infection and HAND.
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